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1. Introduction 
1.1 Ubiquitination: A functional perspective 
Ubiquitination (also referred to as “ubiquitin conjugation” or “ubiquitylation”) is the 
post-translational modification of proteins by the covalent attachment of ubiquitin, a 76 
amino-acid protein. “Monoubiquitination”, the attachment of a single ubiquitin moiety 
involves isopeptide bond formation between the α-carboxy group of the C-terminal 
Glycine residue of ubiquitin and the ε-amino group of a lysine residue in the target 
protein. In addition to being modified by single ubiquitin moieties, proteins can also be 
modified by chains of ubiquitin (“polyubiquitination”). Polyubiquitin chain formation 
takes place by subsequent attachment of ubiquitin moieties linked to one of the lysine 
residues present in the previously added ubiquitin. Of all the known consequences of 
ubiquitination, the targeting of proteins for degradation has been best characterized. 
Substrates tagged with a polyubiquitin chain are selectively degraded by a multi-
subunit ATP-dependent protease known as the 26S proteasome (reviewed in Glickman 
and Ciechanover, 2002). 
Of the seven lysine (K) residues present in ubiquitin (Figure 1), K48-linked 
polyubiquitin chains are recognized and targeted to the proteasome. Covalent 
attachment of K48-linked tetraubiquitin chain has been shown to be necessary and 
sufficient for recognition and degradation of a model substrate by the 26S proteasome 
in vitro (Thrower et al., 2000). In addition, K11 and K29-linked polyubiquitin chains 
are also reported to target proteins to the proteasome (Johnson et al., 1995; Liu et al., 
1996). The progression of cell cycle (reviewed in Koepp et al., 1999), transcriptional 
regulation (reviewed in Muratani and Tansey, 2003), signal transduction (reviewed in 
Welchman et al., 2005), and antigen presentation (reviewed in Rock and Goldberg, 
1999), are just a few of the many processes regulated by ubiquitin-proteasome-
dependent proteolysis. However, degradation by the proteasome is not the only fate 
possible for ubiquitin tagged proteins. K63-linked polyubiquitin chains can signal 
nonproteolytic, reversible events such as in DNA repair (Spence et al., 1995; Hofmann 
and Pickart, 1999; Hoege et al., 2002), the initiation of the inflammatory response 
(Deng et al., 2000), ribosomal function (Spence et al., 2000), and the regulation of 
certain transcription factors (Kaiser et al., 2000). K63-linked polyubiquitin chains 
Introduction 
 2
might also act as a signal for endocytosis in some cases (Galan and Haguenauer-Tsapis, 
1997; Springael et al., 1999). 
 
Figure 1: Schematic representation of ubiquitin and position of the lysine residues. 
Ubiquitin has seven lysine (K) residues, all of which are supposed to be utilized in ubiquitin 
chain formation. The C- terminal end of ubiquitin has a Glycine residue (G76) through which 
isopeptide bond formation takes place with the substrate or another ubiquitin moiety.  
In contrast to polyubiquitination, monoubiquitination of proteins targets them for 
endocytosis and lysosomal degradation (reviewed in Hicke and Riezman, 1996; 
Haglund et al., 2003). In addition, monoubiquitination can also act as a regulatory 
modification such as in protein sorting, histone function and transcription (reviewed in 
Hicke, 2001; Katzmann et al., 2002). 
No matter what the final outcome is, the whole process of ubiquitination is made 
possible through a concerted action of at least three enzymes, in a three-step 
mechanism referred to as the ubiquitin-conjugation cascade (see below). Since 
ubiquitination regulates a number of cellular pathways, it is unsurprising that 
deregulation of the ubiquitin-conjugation system has been implicated as a causative 
factor in cancer and other human diseases (reviewed in Glickman and Ciechanover, 
2002; Ciechanover and Brundin, 2003; Pagano and Benmaamar, 2003). 
1.2 The ubiquitin-conjugation cascade  
As mentioned earlier, ubiquitination of a substrate protein involves the isopeptide bond 
formation between the α-carboxy group of the C-terminal Glycine residue (G76) of 
ubiquitin and the ε-amino group of a lysine of a target protein. More rarely, it can also 
be conjugated to the α-amino group at the N-terminus (Breitschopf et al., 1998; Aviel 
et al., 2000; Reinstein et al., 2000; Bloom et al., 2003). For ubiquitination to take place 
the sequential action of three enzymes, namely the ubiquitin-activating enzyme E1 
(UBA), ubiquitin-conjugating enzyme E2 (UBC), and ubiquitin-protein ligase E3 is 
required. Firstly, the E1 adenylates the C-terminus of ubiquitin and then forms a 
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thioester bond between the C-terminus of ubiquitin and a catalytic E1 cysteine residue 
(Figure 2).  
 
Figure 2: The ubiquitin-conjugation cascade. Free ubiquitin (Ub) is activated in an 
ATP-dependent manner by the activity of an ubiquitin-activating enzyme (E1), which 
hydrolyses ATP and forms a thioester bond with ubiquitin. Subsequently, ubiquitin is 
transferred to one of many distinct ubiquitin-conjugating enzymes (E2). In some reactions, E2s 
can directly ubiquitinate substrates, whereas others require the help of a ligase (E3). While 
some E3s have the ability to form ubiquitin thioester during the transfer of ubiquitin to the 
substrate, others support ubiquitination by recruiting substrates to E2 enzymes. Usually, several 
ubiquitin molecules, in the form of a polyubiquitin chain, are conjugated to a substrate. In some 
cases, this requires a specific polyubiquitin chain-assembly factor (E4). Based on the number of 
ubiquitins (monoubiquitin versus polyubiquitin) and the type of chain linkage (e.g. K48 or 
K63), the fate of the substrate protein is decided. Ubiquitin modification can simultaneously be 
removed by deubiquitinating enzymes (DUB). The attachment of ubiquitin to the substrate 
could also act as signal for the recruitment of ubiquitin-binding proteins (UBP), which could 
either protect the substrate from deubiquitination and/or act as a bridging factor to transfer 
polyubiquitinated substrates to the proteasome (Adapted and modified from Passmore and 
Barford, 2004). 
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To be fully active, the E1 must non-covalently bind to, and adenylate a second 
ubiquitin molecule. Secondly, the thioester-linked ubiquitin is transferred from E1 onto 
the active site cysteine residue of one of a number of E2s, where it is again linked by a 
thioester bond. Finally, with the help of a third enzyme, the E3 ligase, ubiquitin is 
transferred from the E2 to a lysine residue of a substrate protein (reviewed in Passmore 
and Barford, 2004). This final transfer of ubiquitin to the substrate results in an 
isopeptide bond between a substrate lysine and ubiquitin. In addition, E3s can also 
catalyze ubiquitin-ubiquitin conjugation to form a polyubiquitin chain. Although the 
precise mechanisms vary among the different E3s, they all promote the transfer of 
ubiquitin, either directly or indirectly, from an E2 to a substrate or another ubiquitin. In 
addition to the aforementioned components of the ubiquitin conjugation cascade, other 
conjugation factors, or accessory factors have been identified to play a role in either 
polyubiquitin chain assembly or in delivering ubiquitinated substrates to the 
proteasome (see below). Furthermore, concurrent to the conjugation of ubiquitin to 
substrate proteins, the action of deubiquitinating enzymes (DUBs) antagonizes 
polyubiquitin chain assembly thus adding another layer of selectivity and regulation 
(reviewed in Wilkinson, 2000).  
1.2.1 Ubiquitin-activating enzyme E1 
The first evidence towards understanding the physiological role of ubiquitination was 
demonstrated by using cells expressing a temperature sensitive mutant of E1 (Finley et 
al., 1984). Cells expressing the temperature sensitive form of E1 underwent cell cycle 
arrest at the nonpermissive temperature and failed to degrade short-lived proteins. In 
yeast, E1 has been shown to be an essential enzyme (McGrath et al., 1991). 
Furthermore, in most eukaryotes, a single E1 activates ubiquitin for all downstream 
processes. The E1 protein is approximately 100 kDa in size and exists as two isoforms 
in humans (Cook and Chock, 1992).  
1.2.2 Ubiquitin-conjugating enzyme E2 
More than thirty E2 enzymes have been identified so far, which mediate transfer of 
ubiquitin from E1 to E3. While the genome of S.cerevisiae encodes 13 E2-like 
enzymes, there might be up to 96 different E2s in humans (Weissman, 2001; Vaux and 
Silke, 2005). The family of E2s is structurally well characterized and shares a 
conserved approximately 150 amino acid core domain through which E2s interact with 
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E1. In addition, many E2s have a non-conserved amino or carboxy terminal extension, 
which is supposedly involved in mediating specific interactions with E3s (Pickart, 
2001). While most of the E2s identified are less than 35 kDa, there are few exceptions 
such as the 523 kDa E2 named BRUCE (BIR Repeat containing ubiquitin conjugating 
enzyme) (Hauser et al., 1998). 
1.2.3 Ubiquitin-protein-ligase E3 
Of the three principle enzymes involved in ubiquitin conjugation, it is mainly the E3, 
which mediates substrate recognition. Based on the presence of conserved protein 
domains and the mechanistic role they play, E3s can be broadly classified into RING 
E3s and HECT E3s. 
1.2.3.1 RING E3 
The RING (Really Interesting New Gene) family of E3s is the largest family of E3s 
identified so far (Borden, 2000). Members of this family contain a RING finger or 
RING finger-like (see below) domain and are assumed to function predominantly as 
molecular scaffolds that bring other proteins together rather than as chemical catalysts. 
The RING finger domain consists of a series of histidine and cysteine residues with a 
characteristic spacing that allows for the coordination of two zinc ions in a cross brace 
structure.  
RING E3s can further be classified into two subtypes; a) single-subunit RING E3s and 
b) multi-subunit RING E3s. The single-subunit E3s consist of a single polypeptide that 
possesses the capacity to recognize the ubiquitination signals in their specific substrates 
through domains that, in general, are structurally distinct from the RING finger. Single-
subunit RING E3s include Mdm2, which ubiquitinates p53 and c-Cbl, which is 
involved in down-regulation of growth factor receptors (reviewed in Pickart, 2001). In 
the multi-subunit RING E3s, the substrate recognition and the RING finger are on 
separate subunits. The SCF (Skp1-Cullin-F-box protein), the APC, and the VCB types 
belong to this class of multi-subunit RING E3s (reviewed in Deshaies, 1999).  
In addition to the RING finger domain two closely related domains, the U-box 
(Hatakeyama et al., 2001) and the PHD/LAP (plant homeodomain or leukemia-
associated protein) domains have shown to confer E3 activity (Boname and Stevenson, 
2001). Though these motifs cannot bind zinc, they take up a RING-finger like 
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conformation and are maintained by salt bridges and hydrogen bonds (Aravind and 
Koonin, 2000). 
1.2.3.2 HECT E3 
The family of HECT (Homologous to E6-AP C-Terminus) domain E3s has been named 
after their founding member E6-AP (further described in section 1.3) (Huibregtse et al., 
1995). Members of this family of E3 ligases are characterized by the presence of a 
conserved catalytically active C-terminal region of approximately 350 amino residues, 
called the HECT domain. This catalytic activity is mediated by a conserved cysteine 
residue positioned approximately 35 residues upstream of the C-terminus within the 
HECT domain, which acts as a site of ubiquitin thioester formation (Huibregtse et al., 
1995; Scheffner et al., 1995). HECT domain proteins have a modular structure 
consisting of the C-terminal HECT domain and a variable N-terminal extension. While 
the HECT domain is required for interactions with their cognate E2, the N-terminus is 
presumably involved in determining the substrate specificity of the individual E3. Even 
though the crystal structure of HECT E3s in complex with their cognate E2s are 
available (Huang et al., 1999; Verdecia et al., 2003; Zheng, 2003), the mechanism of 
how exactly ubiquitin is transferred from E2 to E3 and from E3 to the substrate remains 
ill-defined.  
1.2.4 Accessory factors 
The conjugation factors labeled as ‘E4s’ help in polyubiquitin chain assembly by 
extending nascent chains rather than extending ubiquitin chains already attached to a 
substrate. This family includes the yeast UFD2 protein that has been shown to display 
E4 activity by binding to ubiquitin moieties of preformed conjugates and catalyzing 
polyubiquitination (Koegl et al., 1999). In addition to E4 other accessory factors are 
involved in recognizing polyubiquitin labeled substrates and delivering them to the 
proteasome. These include distinct families of chaperones or “shuttle factors” 
(Hartmann-Petersen et al., 2003). 
1.3 E6-AP (E6-Associated Protein) 
The cellular ubiquitin-protein ligase E6-AP was originally identified by its ability to 
interact with the E6 oncoprotein of HPVs associated with cervical cancer and, in 
complex with E6, to target p53 for ubiquitin-mediated proteasomal degradation 
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(Huibregtse et al., 1991; Scheffner et al., 1993). As mentioned earlier, it is also the 
founding member of the HECT family of ubiquitin-protein ligases. The gene encoding 
E6-AP (UBE3A) has been localized to the region q11-q13 of chromosome 15 (Nakao et 
al., 1994). Five mRNA subtypes of E6-AP encoding three potential isoforms have been 
identified (Yamamoto et al., 1997). These isoforms are approximately 100 kDa in size 
and vary at their N-terminal region. Whether these isoforms differ in functionality is 
not known. In addition to its E3 activity E6-AP has also been reported to serve as a 
transcriptional coactivator for steroid hormone receptors (Nawaz et al., 1999). 
Furthermore, these functions have been shown to be separable and independent of one 
another.  
Understanding the physiological role of E6-AP is still of interest because inactivation 
of UBE3A gene has been associated with Angelman Syndrome, a hereditary 
neurological disorder (see 1.3.4). Moreover, in the case of cervical cancer, the E6/E6-
AP complex not only targets p53 for ubiquitin-mediated degradation, but also targets 
other proteins (see 1.3.3), which is necessary for HPV-induced cervical carcinogenesis. 
1.3.1 Human papillomaviruses (HPVs) and cervical cancer 
HPVs are small DNA-viruses that belong to the family Papovaviridae. Productive 
infection with HPVs has long been known to result in benign squamous epithelial 
lesions, commonly known as warts. More than 130 HPV types have been isolated from 
epithelial cells of the skin, anogenital, or oropharyngeal mucosa. Of these, some types 
of HPV have also been found in samples of patients with cancers of the oral cavity, 
skin cancers of immunosuppressed patients and, most notably cancer of the uterine 
cervix (cervical cancer) (reviewed in zur Hausen, 1996). 
Cervical cancer represents the second most common form of cancer in women. In 
greater than 90% of the cases, at least one copy of the HPV viral genome has been 
found integrated into the host-cell genome. Furthermore, continuous expression of the 
viral E6 (approximately 150 amino acids) and E7 (approximately 100 amino acids) 
oncoproteins is required for the malignant phenotype of cervical carcinoma cell lines. 
These oncoproteins have been found to possess cell-transforming and cell-
immortalizing potentials in cell culture systems. Taken together, the above evidence 
has led to the causal association of HPV with cervical cancer (reviewed in zur Hausen, 
1996; 2000). 
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Of around 40 HPV types isolated from the anogenital tract, only few have been 
associated with malignant lesions. Based on their clinical association with cervical 
carcinogenesis HPVs can be classified as “high risk” or “low risk” types. High risk 
HPVs including the type 16, 18, 31, 33, 39, 45, and 52 are associated with malignant 
lesions. In comparison to high risk HPVs, the low risks HPVs such as type 6 and 11 can 
be associated with benign lesions such as genital warts (condylomata acuminata).  
Studies to elucidate the role of high risk HPVs in cervical carcinogenesis have shown 
that the E6 protein interacts with the p53 tumour suppressor protein (Werness et al., 
1990) and E7 with the retinoblastoma gene product p110RB and the p110RB related 
proteins p107 and p130 (henceforth collectively referred to as pRB) (Dyson et al., 
1989). Subsequently both p53 and pRB have been shown to be targeted for inactivation 
by ubiquitin-mediated proteasomal degradation (Scheffner et al., 1990; Crook et al., 
1991; Dyson et al., 1992; Boyer et al., 1996).  
1.3.1.1 E7 and pRB 
In normal cells (HPV-negative cells) the pRB family of proteins (also referred to as 
“pocket proteins”) regulate progression of the cell cycle from G0/G1 into S phase, by 
interacting with the E2F/DP family of transcription factors (referred henceforth 
collectively as “E2F”). E2F is known to transactivate many genes required for DNA 
replication. Hence, binding of pRB in its active, growth suppressive form to E2F not 
only interferes with its transactivation properties, but is also said to convert E2F into a 
transcriptional repressor (Dyson, 1998), thus limiting the cell from transition into S 
phase. Cell cycle-dependent phosphorylation of pRB leads to disruption of E2F/pRB 
complex and reverses the pRB-mediated cell cycle arrest resulting in cell cycle 
progression. In HPV-positive cells, analogous to the phosphorylation of pRB, binding 
of E7 to pRB and subsequent degradation results in the release of transcriptionally 
active E2F complex driving cells into S phase. Since HPVs propagate in differentiated 
non-dividing cells it is imperative that the infected cells are driven into S phase to allow 
viral replication (Stubenrauch and Laimins, 1999).  
The mechanism of E7 mediated degradation of pRB is unclear. Whether E7 in 
conjugation with another protein acts as an E3 ligase to target pRB for ubiquitination 
and degradation is not known. Interestingly, E7 has been shown to directly interact with 
the S4 ATPase subunit of the 19S regulatory complex of the 26S proteasome 
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suggesting that E7 could directly target pRB for degradation without prior 
ubiquitination (Berezutskaya and Bagchi, 1997). However whether this is true remains 
to be determined. 
1.3.1.2 E6 and p53 
The p53 tumour suppressor protein is known to play a critical role in cellular responses 
to various stress signals (Harris and Levine, 2005). In normal cells (HPV-negative 
cells), p53 is predominantly regulated by a negative feed-back loop with Mdm2, a 
RING finger ligase that targets p53 for proteasomal degradation (Haupt et al., 1997; 
Kubbutat et al., 1997). However under stress conditions inactivation of the Mdm2 feed-
back loop leads to stabilization of p53 levels and increased transcriptional activity, the 
outcome of which leads to cell-cycle dependent growth arrest, senescence or apoptosis. 
In contrast to most cancers, wherein the p53 gene is mutated (greater than 40%), it is 
rarely mutated in HPV-positive cervical carcinomas (Hainaut et al., 1998). Thus it has 
been hypothesized that the inactivation of the normal functions of p53 by E6 is similar 
to the inactivation of p53 by mutation and is a key step in HPV-induced cervical 
carcinogenesis. In contrast to E7 wherein the biochemical mechanism of pRB 
degradation remains poorly understood, E6 mediated degradation of p53 has been 
shown to involve the recruitment of E6-AP (Huibregtse et al., 1991). 
1.3.2 The E6-E6-AP-p53 interaction 
The biochemical mechanism by which high risk E6s target p53 for inactivation is well 
characterized (Figure 3). In the initial step, E6 forms a complex with E6-AP. This 
dimeric complex recognizes p53, binds to it and polyubiquitinates p53 with the help of 
ubiquitin-conjugating enzymes (UbcH5, UbcH7, or UbcH8). In the final step, p53 is 
recognized and degraded by the 26S proteasome. It should be noted that E6 or E6-AP 
alone are not able to enter into a complex with p53 and it is still unclear whether E6 or 
E6-AP or both actually directly contact p53. In comparison to high risk E6s, the low 
risk E6s are unable to target p53 for degradation.  
Mutational analysis to study the interaction of E6-AP with E6 has identified three 
functional domains which are required for 1) Binding with E6, 2) E6 dependent 
association with p53 and 3) E6 dependent ubiquitination of p53 (Figure 4) (Huibregtse 
et al., 1993). An 18 amino acid region (amino acids 378-395) within the central portion 
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of E6-AP was found to be necessary and sufficient for binding with E6 of high risk 
HPVs. The region that directs E6 dependent association with p53 spans approximately 
500 amino acids (amino acids 266-768) and includes the E6 binding domain. E6-AP 
sequences in addition to those required for formation of a stable ternary complex with 
E6 and p53 are necessary to stimulate the ubiquitination of p53 (amino acids 768-852). 
These sequences lie within the C-terminal 84 amino acids of E6-AP and encompass the 
HECT domain. Furthermore, a catalytical cysteine residue (C820) within the HECT 
domain is required for thioester formation (Huibregtse et al., 1995; Scheffner et al., 
1995). 
 
Figure 3: Model for the ubiquitination and degradation of p53 in HPV-positive 
cells. In HPV-positive cervical cancer cells, the E6 oncoprotein forms a complex with the 
cellular ubiquitin-ligase E6-AP which then targets p53 for polyubiquitination and subsequent 
degradation by the 26S proteasome. However in normal cells (HPV-negative), p53 is 
predominantly targeted for degradation by the RING ligase, Mdm2. Ub- ubiquitin.  
While the mechanism of E6/E6-AP targeted ubiquitination of p53 is clear and can be 
reconstituted in vitro using purified enzymes (Scheffner et al., 1993; Rolfe et al., 1995), 
it remains unclear how exactly polyubiquitinated p53 is delivered to the proteasome for 
degradation. Recent studies suggest that the human homologue to RAD23 (hHR23) 
protects polyubiquitinated p53 from deubiquitination and could act as a bridging factor 
to deliver polyubiquitinated p53 to the proteasome (Glockzin et al., 2003). 
Interestingly, hHR23 is also known to interact and is a substrate of E6-AP (see section 
1.3.5). 
Introduction 
 11
 
Figure 4: Schematic representation of the regions of E6-AP that direct E6 binding, 
E6 dependent association with p53, and E6 dependent ubiquitination of p53. 
Mutational analysis of E6-AP has mapped a central 18 amino acid region that is sufficient for 
binding to E6 (amino acids 378-395). Amino acid 266-768 is the minimal region required for 
p53 associated in complex with E6 and includes the E6 binding region. In addition to this, the 
last 84 amino acids (amino acids 768-852) of the HECT domain is critical for E6 dependent 
ubiquitination of p53 (Huibregtse et al., 1993). 
Even though in HPV-positive cancer cells E6-AP targets p53 for degradation (i.e in 
presence of E6), E6-AP does not appear to regulate p53 stability in HPV-negative cells 
(Beer-Romero et al., 1997; Talis et al., 1998; Traidej et al., 2000). Investigation of the 
MDM2-pathway of p53 regulation in HPV-positive cell lines has indicated that the 
MDM2-mediated degradation pathway is inactive (Hengstermann et al., 2001). Hence, 
the degradation of p53 is dependent entirely on the E6/E6-AP pathway in HPV-positive 
cells. Therefore, studies in which E6 mediated degradation of p53 was inhibited by 
either using peptide aptamers or RNA interference has led to stabilization of p53 which 
restores its transactivating properties and tumour suppressor functions in HPV-positive 
cells (Butz et al., 2000; Butz et al., 2003). Similarly interfering with E6-AP expression 
using antisense oligonucleotides or ribozyme-based gene inactivation leads to p53 
stabilization (Beer-Romero et al., 1997; Kim et al., 2003). 
Initially it was believed that the anti-apoptotic properties of high risk E6s were 
attributed to its ability to target p53 for degradation. However, several lines of evidence 
later suggested that high risk E6s also possess p53-independent anti-apoptotic 
properties (Pan and Griep, 1995; Spitkovsky et al., 1996). Search for additional cellular 
targets of E6 that contribute to its anti-apoptotic potential has led to the identification of 
several proteins which interact with high risk E6 (Table 1) (reviewed in Munger and 
Howley, 2002; zur Hausen, 2002). Of these, several have been shown to be targeted for 
degradation either in an E6-AP-independent or E6-AP-dependent manner. 
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Cellular proteins that interact with E6 
(Reference) 
Degradation 
by E6 
E6-AP 
dependent 
Bak (Thomas and Banks, 1999) + + 
E6BP/ERC-55 (Chen et al., 1995) - - 
E6TP1 (Gao et al., 1999) + + 
hAda3(Kumar et al., 2002) + ? 
hDlg (Kiyono et al., 1997) + +/- 
hScrib (Nakagawa and Huibregtse, 2000) + + 
IRF-3 (Ronco et al., 1998) - - 
MAGI 
(Glaunsinger et al., 2000; Thomas et al., 2002) 
+ - 
MCM7 (Kuhne and Banks, 1998) + + 
MUPP1 
(Lee et al., 2000) 
+ - 
NFX1-91 (Gewin et al., 2004) + + 
p300/CBP (Patel et al., 1999) - - 
PKN (Gao et al., 2000) - - 
Tyk2 (Li et al., 1999) - - 
Paxillin (Tong and Howley, 1997) - - 
Table 1 Cellular proteins that are known to interact with high risk E6s. Proteins 
that are degraded by E6 (+) in an E6-AP- independent (-) or E6-AP-dependent manner 
(+) are indicated. (?) Not known. +/- Conflicting evidence.  
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1.3.3 E6-dependent substrates of E6-AP 
As indicated in Table 1, the high risk E6s are known to interact with several proteins 
that contain PDZ (PSD95/Dlg/ZO-1) domains (i.e., hScrib, MUPP-1, hDlg and MAGI-
1) (Mantovani and Banks, 2001). Multi-PDZ domains form modular structures that are 
involved in protein-protein interaction with membrane or cytoskeletal proteins. Of the 
PDZ domain-containing proteins that interact with E6, the human homologue to the 
Drosophila Scribble (Vartul) tumour suppressor protein (hScrib) has been shown to be 
targeted for degradation by E6 in an E6-AP-dependent manner (Nakagawa and 
Huibregtse, 2000; Nakagawa et al., 2004). hScrib localizes to basolateral regions of 
epithelial cells and is down-regulated by E6/E6AP with the progression of normal 
uterine cervical cancer tissue to invasive cervical cancer. The ability of E6 to interact 
with, and possibly degrade PDZ domain proteins is said to contribute to the oncogenic 
potential of E6 (Kiyono et al., 1997; Mantovani and Banks, 2001). Interestingly, the 
PDZ domain proteins MAGI-1/2/3 and MUPP1 are targeted for degradation by E6 in 
an E6-AP independent manner, suggesting that an E3 ligase other than E6-AP may be 
involved (Glaunsinger et al., 2000; Lee et al., 2000; Thomas et al., 2002). 
Earlier studies have indicated that the ability of E6 to immortalize epithelial cells is 
partly dependent on its ability to increase telomerase activity (Klingelhutz et al., 1996) 
and this is brought about by induction of expression of the catalytic-rate limiting 
subunit of telomerase called, hTERT (Kiyono et al., 1998; Gewin and Galloway, 2001; 
Oh et al., 2001; Veldman et al., 2001). More recently, this ability of E6 to induce 
telomerase activity has been shown to be dependent on E6-AP and involves the 
degradation of NFX1-91 (nuclear factors that binds to the X1 box), a repressor of 
hTERT (Gewin et al., 2004; Liu et al., 2005). In addition to degrading p53 and 
inducing of telomerase activity, the ability of high risk E6 to immortalize certain 
epithelial cells has been found strongly correlate with its ability to bind to and target 
E6TP1 (E6 targeted protein 1), a Rap GTPase-activating protein (RapGAP) for 
degradation (Dalal et al., 1996; Kiyono et al., 1998; Gao et al., 1999; Gao et al., 2001). 
Degradation of E6TP1 has also been shown to be mediated by E6 in E6-AP dependent 
manner (Gao et al., 2002).  
Thus the presence of E6 redirects the ability of E6-AP to ubiquitinate its normal 
substrates and thus alters it substrate specificity. In addition, E6 has been found to 
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promote autoubiquitination and degradation of E6-AP itself thereby reducing its half-
life (Kao et al., 2000). Whether dysregulation of E6-AP mediated ubiquitination of its 
normal substrates also contributes to the transforming function of E6 in HPV-positive 
cells is unclear. 
1.3.4 Angelman syndrome (AS)  
Angelman syndrome is a neurological disorder which has an occurrence of 1:15000 
births and is characterized by severe mental retardation, ‘puppet-like’ ataxic gait with 
jerky arm movements, seizures, EEG abnormalities, hyperactivity, and bouts of 
inappropriate laughter. (Williams et al., 1995; Kishino et al., 1997; Matsuura et al., 
1997). AS is one of the best studied cases of genetic disorders, in which imprinting 
plays a role. In most tissues, the UBE3A gene displays bi-allelic expression but is 
maternal-specific in certain brain areas due to paternal imprinting (Rougeulle et al., 
1997). Thus loss or inactivation of the maternal allele of UBE3A in brain causes AS. 
Studies conducted on AS patients indicate that approximately 70% involve maternal 
deletions at chromosome 15q11-q13, 2% involve paternal uniparental disomy (UPD) at 
this region, and 2-3% result from imprinting mutations that alter the methylation 
pattern at this region. The remaining 25% of the cases show biparental inheritance 
without methylation abnormalities or deletions (Kishino et al., 1997). As mentioned 
earlier, E6-AP has two separable functions, one as an E3 ligase and another as a 
transcriptional coactivator. To determine the pathogenesis of AS, mutants of E6-AP 
obtained from AS patients have been studied. In majority of these cases loss of E3 
ligase activity of E6-AP has been detected whereas the coactivator function is found to 
be intact (Nawaz et al., 1999; Cooper et al., 2004), thus suggesting that deregulated 
degradation of one or more of its substrates could be responsible for the pathogenesis of 
AS.  
In order to study the causal relationship between inactivation of UBE3A and Angelman 
syndrome, mouse models have also been constructed in which UBE3A has been 
inactivated (Jiang et al., 1998; Miura et al., 2002). Mice with maternal deficiency (m-
/p+) for UBE3A resembles human AS with motor dysfunction, inducible seizures, and a 
context dependent learning deficit. Mouse models of AS like the human counterparts 
display imprinted expression in hippocampus and purkinje neurons (Albrecht et al., 
1997). 
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1.3.5 E6-independent substrates of E6-AP 
Since loss in E3 ligase activity is supposedly responsible for pathogenesis of AS 
patients, several labs have tried to identify potential substrates of E6-AP which can be 
bound and ubiquitinated in an E6-independent manner. Interestingly, E6-AP itself is 
found to serve as a substrate undergoing autoubiquitination by a mechanism which is 
predominantly intermolecular (Nuber et al., 1998). In addition, the human homologs of 
S. cerevisiae RAD23, (HHR23A and HHR23B) (Kumar et al., 1999), the Src tyrosine 
non receptor kinase Blk (B lymphocyte specific receptor kinase) (Oda et al., 1999), and 
the multicopy maintenance protein (Mcm) 7 subunit of the replication licensing factor-
M (Kuhne and Banks, 1998) have been found to be ubiquitinated by E6-AP. However, 
of the identified substrates of E6-AP none have been correlated to pathogenesis of AS. 
1.4 RNA interference (RNAi)  
Till recently, the functional characterization of a particular mammalian gene or gene 
product involved either elimination by gene knock-out strategies in mouse models, or 
inactivation using ribozymes, antisense or overexpression of a dominant-negative form 
of the protein product in cell culture systems. The recent discovery of the natural 
process termed RNA interference (RNAi) offers an alternate tool to functionally 
characterize a gene product (Fire et al., 1998).  
RNAi is an antiviral post-transcriptional gene silencing defense mechanism in animals 
and plants caused by the introduction of double-stranded RNA homologous to the 
silenced gene (reviewed in Paddison and Hannon, 2002; Denli and Hannon, 2003). This 
mechanism of RNAi has been found to be conserved in most organisms with the 
notable exception of the yeast, Saccharomyces cerevisiae (Hutvagner and Zamore, 
2002). RNAi involves the cleavage of the double stranded RNA (Figure 5B) by an 
RNase III enzyme (DICER) into smaller fragments of 21-23 nucleotides (nt) in length 
with characteristic dinucleotide 3’ overhangs referred to as small interfering RNA 
(siRNA) (Figure 5A) (Zamore et al., 2000). The siRNA is then recruited into a 
multienzyme complex called RNA induced silencing complex (RISC) which binds 
specifically to complementary mRNA transcript to target it for cleavage and 
degradation. 
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Figure 5: RNA interference. A. Schematic representation of a synthetic 21 nucleotide 
duplex small interfering RNA (siRNA) with 2 nucleotide overhangs at each 3 prime end. B. 
Schematic representation of RNAi pathway. Long double stranded siRNA is cleaved into short 
siRNAs by RNase III enzyme complex (DICER) in an ATP dependent manner. The antisense 
strand of the siRNA duplex is then recruited into a RNA induced silencing complex (RISC) 
which specifically recognizes and cleaves the complementary mRNA (adapted from 
Dykxhoorn et al., 2003)
Initially, RNAi was not used in mammalian studies, because RNA duplexes larger than 
30bp are known to trigger generalized cellular responses, predominantly through 
activation of dsRNA dependent-protein kinases. However, this limitation has been 
overcome by the use of synthetic double stranded small interfering RNA (siRNA) of 21 
nucleotides in length with overhanging 3’ dinucleotides (Elbashir et al., 2001). While 
this approach overcomes the cellular non-specific response to a certain extent, it is 
limited to transient studies due to the fact that the siRNA gets depleted at each cell 
division. In order to overcome the transient nature of synthetic siRNA, DNA based 
vector systems have been created whereby it is possible to bring about stable 
suppression of gene expression (summarized in Paddison and Hannon, 2002). These 
vectors utilize RNA polymerase III based promoters (e.g. U6 and HI RNA) to express 
short hairpin like RNA (shRNA) transcripts with a dinucleotide 3’ overhang that can 
act as siRNA molecules.  
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Recently, a class of endogenous non-coding RNA molecules called microRNAs 
(miRNAs) have been found in most organisms (reviewed in Dillon et al., 2005). These 
miRNAs, like siRNA can also be recruited into RISC, but unlike siRNAs 
predominantly lead to translational repression by binding to the 3’untranslated region 
(UTR). In comparison to siRNAs, miRNA have been found to require weak 
complementation with the target sequence to facilitate translational repression (Grishok 
et al., 2001; Hutvagner et al., 2001; Ketting et al., 2001). Functionally miRNA play an 
important role in developmental regulation, and normal physiology. Interestingly, 
misexpression of miRNAs has been observed in many cancers, suggesting that 
miRNAs may also have a role to play in carcinogenesis (Calin et al., 2002; Calin et al., 
2004). The finding that miRNAs can also function as siRNA suggests that the eventual 
mechanism of post-transcriptional genes silencing, i.e. translational repression or 
mRNA degradation, is probably decided by the extent of complementarity between the 
regulatory RNA and its target (Doench et al., 2003; Zeng et al., 2003). 
1.5 Bimolecular fluorescence assay 
Recent evidence suggests that localization of substrate and enzyme complexes to 
distinct organelles or compartments could give another dimesion of regulation and 
substrate specificity (reviewed in Pines and Lindon, 2005). Even though the 
biochemical properties of E6-AP have been well characterized, the subcellular 
localization of individual protein interactions is poorly characterized. Studies to 
determine the subcellular localization of E6-AP indicated it to be distributed equally in 
the nucleus and cytoplasm (Hatakeyama et al., 1997). Although a number of potential 
partners which can interact with E6-AP in an E6 dependent/independent manner have 
been identified, it is unclear if localization plays a role in substrate preference. 
Recently, a new technique called Bimolecular Fluorescent Complementation (BiFC) 
was reported for visualizing protein complexes in living cells (Hu et al., 2002). This 
approach involves creating fusion proteins of non-fluorescent N-terminal or C-terminal 
fragments of the yellow fluorescent protein (YFP) with individual interacting partners 
of the protein complex to be studied (Figure 6). Co-expression of the N and C –terminal 
YFP fragments alone within cells does not lead to fluorescence. However, when fused 
to two separate interacting partners, the interaction between the two proteins leads to 
fluorescence complementation allowing visualization of the complex. This method has 
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the advantage of not requiring sophisticated instruments in comparison to other 
techniques for visualizing protein interactions (e.g. FRET). In addition, BiFC has been 
used for visualizing multiple protein interactions and to study the relative efficiencies 
of complex formation of the various interacting partners (Hu and Kerppola, 2003; 
Grinberg et al., 2004). 
 
Figure 6: Bimolecular fluorescence assay. Two potential interacting proteins (indicated in 
Red and blue) are tagged with the two non fluorescent fragment of the yellow fluorescent 
protein (YFP) (indicated in grey). In order to reconstitute the fluorophore, the two fragments 
should come into close proximity which is made possible by the interacting proteins. 
Fluorescence reconstitution can be used as an indicator to study complex formation and 
localization (adapted from Hu et al., 2002)
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2. Aim 
E6-AP interacts with the E6 oncoprotein of cancer-associated HPVs and, in complex 
with E6 targets the tumour suppressor p53 for proteasomal degradation. In contrast to 
most cancers wherein the p53 gene is mutated or not expressed, it is rarely mutated in 
HPV-positive cervical carcinomas. This has led to the assumption that targeted 
inactivation of p53 by the E6/E6-AP complex is functionally equivalent to the 
inactivation of p53 by mutation. Thus, the aim of this study was to determine the effect 
of E6-AP inactivation in HPV-positive cervical cancer cells and whether E6-AP 
contributes to the known anti-apoptotic properties of E6. In order to do so, RNAi was 
employed to down regulate E6-AP expression in HPV-positive cervical cancer cell 
lines and its consequences on cell growth were studied. 
Loss of E6-AP function has been associated with the development of Angelman 
Syndrome, a neurological disorder in humans. It has been suggested that deregulated 
degradation of the substrates of E6-AP could be involved in the pathogenesis of the 
disease. However, the identities of the substrate(s) are presently unknown. To study the 
biological importance of E6-AP in HPV-negative cells, E6-AP expression was also 
down-regulated by RNAi in various HPV-negative tumour cell lines and its essentiality 
for cell viability was studied. 
While E6-AP is biochemically well characterized, little is known about it subcellular 
localization and/or whether substrate specificity is dependent on localization to specific 
subcellular organelles/compartments. To determine the subcellular location of the 
interactions of E6-AP with its substrates and to study the dynamics of these interactions 
an attempt was made to establish the bimolecular fluorescence complementation assay. 
 
Material and Methods 
 20
3. Material and Methods 
3.1 Materials 
3.1.1 Buffers  
Buffer Z  
( β galactosidase assay) 
100 mM NaH2PO4 (pH 7.0), 10 mM KCl, 1 mM 
MgSO4, 50 mM β- Mercaptoethanol (storage at -
20° C) 
DNA stop buffer (10X) 60% Saccharose, 0.25M EDTA, small quantity of 
Bromophenolblue 
Stacking gel buffer 0.5M Tris pH-6.8, 0.4% SDS 
Separating gel buffer 1.5M Tris pH-8.8, 0.4% SDS 
Laemmlli running buffer (10X) 250 mM Tris-HCl pH 8.4, 2 M Glycine,1% SDS 
Laemmlli stop buffer (2X) 62.5 mM Tris-HCl pH 6.8, 2% SDS, 10% Glycerin, 
100 mM DTT, 0.001 % Bromophenol blue (storage at 
-20° C) 
Phosphate buffer saline (PBS) 137mM NaCl, 2.7mM KCl, 10.1mM NaH2PO4, 
1.8mM KH2PO4, (pH 7.4) 
TAE-buffer (50X) 2M Tris-HCl,, 950 mM Acetic acid, 50mM EDTA 
TNE-T (wash buffer) 10mM Tris-HCL pH 7.5, 2.5mM EDTA, 50mM 
NaCl, 0.1% Tween 20 
TNN lysis buffer 0.1 M Tris-HCl pH 8.0, 0.1 M NaCl, 1% NP-40 
(IGEPAL), 1mM DTT, 1µg/ml Aprotinin and 
Leupeptin, 1mM PefaBloc SC(Roche, Mannheim) 
Transfer buffer 12.5mM Tris HCl, 100mM Glycine, pH 8.3 
HBS-buffer 20 mM HEPES (pH 7,4), 150 mM NaCl 
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3.1.2 Solutions and stocks 
4% Para formaldehyde fixation solution: 4 g Para formaldehyde was dissolved in 20 
ml ddH2O by stirring at 40°C and adding 3-4 drops of 2M NaOH. After dissolving, the 
volume was adjusted to 90 ml with distilled water. The pH was adjusted to 6.5 and 
volume was made upto 100 ml. 
Gelvatol: 2.4 g of polyvinyl alcohol (Mw 30,000-70,000; Sigma) was added to 6 g of 
glycerol in a 50 ml centrifuge tube and mixed by stirring. To the mixture, 6 ml of 
distilled water was added and the mixture was incubated at room temperature. After 
several hours of incubation at room temperature, 12 ml of 0.2 M Tris/HCl, pH 8.5, was 
added and the mixture was heated to 50°C for 10 min with occasional mixing to 
completely dissolve polyvinyl alcohol. The solution was centrifuged at 5,100 rpm for 
15 min. After centrifugation, 2.5% of diazabicyclo-octane (DABCO), an anti-oxidant 
agent, was added to reduce the bleaching of the fluorescence. The solution was 
aliquoted in 1.5 ml micro centrifuge tubes and stored at -20°C. 
Cycloheximide: 60mg/ml in methanol 
Actinomycin D: 1mg/ml in DMSO 
DAPI (4',6-Diamidine-2'-phenylindole dihydrochloride):  1µg/ml in PBS 
 
3.1.3 Medium 
3.1.3.1 Medium for E.coli 
Luria Broth medium (LB): 10g/L NaCl, 5g/L yeast extract, 10g/L Bacto-Tryptone 
(pH-7.5) 
SOC-medium: 20g/L Tryptone, 5g/L yeast extract, 20mM glucose, 10mM NaCl, 
2.5mM KCl, 10mM MgCl2, 10mM MgSO4 (pH 7.5) 
3.1.3.2 Medium for mammalian cell culture 
For culturing of mammalian cell lines, either RPMI-1640 (Sigma) or DMEM (Sigma) 
supplemented with 10% of Fetal Bovine Serum (FBS) was utilized.  
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3.1.4 Cell strains and cell lines 
3.1.4.1 Bacterial strains 
E. coli DH5α, Genotype: F- φ80d lacZ∆M15 ∆(lac) U169 deo R rec A1 hsdR17 (rk-mk+) 
supE44 λ- thi-1 gyrA96 rel A1 (Gibco BRL) 
E. coli BL 21 (DE3), Genotype: F- ompT hsdSb (rb-mb-)βgal dcm (DE3) (Novagen) 
3.1.4.2 Cell Lines 
-RKO  Rectal colon carcinoma, wt p53 (A. Pause) 
-U2OS Osteosarcoma, wt p53 (T. Rothmann) 
-MCF7 Mammary carcinoma, wt p53 (F. Hoppe-Seyler) 
-H1299 Non small lung carcinoma, p53 null (H. Oie) 
-SAOS-2 Osteosarcoma, p53-null (M. Scheffner) 
-C33A Cervical carcinoma, mutant p53 (R273C), HPV-negative (M. Scheffner) 
-SiHa Cervical carcinoma, wt p53, HPV-16 positive (M. Scheffner) 
-CaSki Cervical carcinoma, wt p53, HPV-16 positive (M. Scheffner) 
-HeLa Cervical carcinoma, wt p53, HPV-18 positive (M. Scheffner) 
3.1.5 Mammalian expression vectors 
Vector Characteristics Reference 
pRc/CMV 
5.5 kb; Ampicillin resistance; Neomycin (G418, 
Geneticin) resistance; CMV promoter; for in vitro 
translation and stable protein expression in 
mammalian cell lines ( HPV cell lines 
exceptional) 
Invitrogen 
pCDNA3.0.HA 
5.4 Kb; Ampicillin resistance;  CMV promoter; 
HA-tag at N-terminal; for  in vitro translation, 
transient protein expression in mammalian cell 
lines 
D. Roth, MPI, 
Frankfurt 
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pEF/V5- His  
6.2 Kb; Ampicillin Resistance; Neomycin 
(G418,Geneticin) resistance;  EF promoter; for  in 
vitro expression, transient and stable protein 
expression in mammalian cell lines 
Invitrogen 
Table 2: Vectors used for cloning and expression in mammalian cells 
3.1.5.1 pRC/CMV constructs: 
β-Gal  A. Hengstermann 
p53  M. Scheffner 
HPV-16 E6 M. Scheffner 
HPV-18 E6 M. Scheffner 
3.1.5.2 Miscellaneous constructs 
pd2YFP Clontech 
peGFP-C2 Clontech 
pHA-CMV.bFos.YC155  Hu et al, Mol.Cell, 2002 
pFLAG-CMV2.bjun.YN155  Hu et al, Mol.Cell, 2000 
3.1.5.3 pcDNA3-HA constructs 
Protein Amino acids 
Restriction 
sites 5’,3’ 
Oligonucleotides 
used 
E6-AP 30-852 Kpn I, Apa I MD1, MD4 
E6-AP ∆E6 * ∆ 378-401 Kpn I, Apa I 
MD1, 
siRNA2mut 
sense, MD4 
E6-AP * 1-852 Kpn I, Apa I 
siRNA2mut 
sense, 
siRNA2mut anti 
* contains silent mutations at RNAi binding site of siE6-AP1 
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HA-E6-AP  S. Glockzin 
HA-E6-AP C820A S. Glockzin 
3.1.5.4 pEF/V5 His constructs 
All E6-AP pEF constructs were generated by sub cloning from pcDNA3-HA. 
Respective HA-E6-AP constructs were digested with BamHI and ApaI, klenow filled 
finally ligated into pEF/V5 His.neo digested with BamHI-PmeI. 
Protein Amino acids 
E6-AP 1-852 
E6-AP  30-852 
E6-AP.mut1  
1-852 (with silent mutation at si/sh-E6-
AP1 target site) 
E6-AP.mut2 
1-852 (with silent mutation at si/sh-E6-
AP2 target site) 
E6-AP ∆E6 ∆ 378-401 
E6-AP ∆E6.mut.pEF/V5 His.hygro K. Martentzoglu and C. Strüh
3.1.6 Molecular weight markers 
DNA-Marker: 
- λ (Lambda)-DNA Hind III-Marker (Invitrogen): 
23130, 9416, 6557, 4361, 2322, 2027, 545, 125 [bp] 
- 100 bp ladder (New England Biolabs): 
1517, 1200, 1000, 900, 800, 700, 600, 500, 400, 300, 200, 100 [bp] 
Protein marker: 
- Prestained Protein Ladder (MBI Fermentas): 
180, 130, 100, 73, 54, 48, 35, 24, 16, 10 [kDa] 
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- MARK12TM Unstained Standard (Invitrogen): 
200, 116.3, 97.4, 66.3, 55.4, 36.5, 31, 21.5, 14.4, 6 [kDa] 
3.1.7 Antibodies 
Antibody Characteristics Dilution  Brand 
Anti-p53  
(IgG Do-1) 
Mouse monoclonal  1:1000 (WB) 
1:200 (IF) 
Dianova 
Anti-Hdm2  
(SMP14) 
Mouse monoclonal 1:1000 (WB) Santa Cruz 
Anti-p53 (1-393) Rabbit polyclonal 1:1000 (WB) Santa Cruz 
anti-rabbit  Peroxidase conjugated, goat 1:5000 (WB) Dianova 
anti-mouse peroxidase conjugated, goat 1:5000 (WB) Dianova 
anti-rabbit IgG  AlexaFluor 568, goat 1:1000 (IF) Molecular 
probes 
anti-mouse IgG  AlexaFluor 568, goat 1:1000 (IF) Molecular 
probes 
anti-HA IgG Mouse monoclonal  1:1000 (WB) Covance 
WB-western blotting, IF-immunofluorescence 
3.1.8 Primers List 
Name Sequence 5’ or 3’ Protein 
siRNA2mut 
sense 
GGCTGTGGAAATGAAGCATGCA
CCAATGAGTTTTGTGCTTC 5’ E6-AP 
siRNA2mut 
anti 
GAAGCACAAAACTCATTGGTGC
ATGCTTCATTTCCACAGCC 3’ E6-AP 
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si5mute1 
TACTACCACCAGTTAACTGAGG
GCTGTGGAAATGAAGCATGTAC
CAATGAATTCTG 
5’ E6-AP 
si5mute2 
GCGGGATCCATGAAGCGAGCAG
CTGCAAAGCATCTAATAGAACG
CTACTACCACC 
3’ E6-AP 
MD1 CGCGGATCCATGTGTGCTTCCTGTCCAAC 5’, BamH I E6-AP  
MD2 GGGGTACCGTATGGCGTACCCATACGACGTC 5’, Kpn I HA-tag 
MD3 TAATGGGCCCGCAGCATGCCAAATCCTTTG 3’, Apa I E6-AP 
MD4 GACTAGTGGGCCCTTACAGCATGCCAAATCCTTTG 3’, Apa I E6-AP 
MD8 ACGCGTCGACCATGAAGCGAGCAGCTGC 5’, Sal I E6-AP 
MD9 CGGGGTACCCAGCATGCCAAATCCTTTGG 3’, Kpn I E6-AP 
MD10 CGGGGTACCAATGAAGCGAGCAGCTGC 5’, Kpn I E6-AP 
 
3.1.9 RNA interference 
3.1.9.1 Synthetic siRNA 
Synthetic siRNA were ordered either from Dharmacon, USA or MWG-Biotech AG, 
Germany. siRNAs were ordered as 19-nt RNA duplexes with 2-nt oligo dT 3’ 
overhangs. In case of siRNA purchased from Dharmacon, individual sense and 
antisense strands were ordered and annealed according to manufacturers instructions. 
siRNA from MWG biotech were purchased as annealed oligos and resolubilised in 
supplied annealing buffer. Stock solutions of 20 µM concentration were stored as 
aliquots at -20°C. The sequences of the various siRNA are given in Table 3. 
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Name  Target  mRNA target sequence 
si-E6-AP1 E6-AP TGAAGCCTGCACGAATGAG 
si-E6-AP2 E6-AP AGATGTGACTTACTTAACA 
si-Hdm2 Hdm2 CAAGAGACCCUGGUUAGAC 
si-Control Renilla luciferase AAACAUGCAGAAAAUGCUG 
Table 3 Sequence of synthetic siRNA used for transfection into mammalian cells 
 
3.1.9.2 shRNA vectors 
 
Vector characteristics Reference 
pSUPER shRNA vector driven by H1 RNA polmerase 
III promoter. Ampicillin resistance for 
selection in bacteria. No resistance marker 
for selection in mammalian cell lines 
(Brummelkamp 
et al., 2002b) 
pRetro.SUPER.puro 6.4 kb. derived from the Murine embryonic 
Stem Cell Virus (pesky). shRNA vector 
driven by H1 RNA polymerase III promoter. 
Ampicillin resistance for selection in 
bacteria. No resistance marker for selection 
in mammalian cell lines. Can be used to 
generate virus by transfecting into a suitable 
packaging cell line or can be transfected into 
mammalian cell lines. 
(Brummelkamp 
et al., 2002a) 
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3.1.9.3 Synthetic oligonucleotides used for construction of shRNA 
expression vectors 
Name Sequence 
suprp53fwd 
AGCTTTTCCAAAAAGACTCGAGTGGTAATCT
ACTCTCTTGAAGTAGATTACCACTGGAGTCG
GG 
suprp53rev 
GATCCCCGACTCCAGTGGTAATCTACTTCAA
GAGAGTAGATTACCACTGGAGTCTTTTTGGA
AA  
suprE6AP174fwd 
GATCCCCACTCTGTGATCCTCATCCCTTCAA
GAGAGGGATGAGGATCACAGAGTTTTTTGG
AAA  
suprE6AP174rev 
AGCTTTTCCAAAAAACTCTGTGATCCTCATC
CCTCTCTTGAAGGGATGAGGATCACAGAGTG
GG 
suprE6AP202fwd 
GATCCCCGGAGCAAGCTCAGCTTACCTTCAA
GAGAGGTAAGCTGAGCTTGCTCCTTTTTGGA
AA 
suprE6AP202rev 
AGCTTTTCCAAAAAGGAGCAAGCTCAGCTTA
CCTCTCTTGAAGGTAAGCTGAGCTTGCTCCG
GG 
suprE6AP2421fwd 
GATCCCCTGGCCCAGACACAGAAAGGTTCA
AGAGACCTTTCTGTGTCTGGGCCATTTTTGG
AAA 
suprE6AP2421rev 
AGCTTTTCCAAAAATGGCCCAGACACAGAA
AGGTCTCTTGAACCTTTCTGTGTCTGGGCCA
GGG 
 
3.1.9.4 pSUPER constructs (without selection marker) 
pSUPER constructs were generated by annealing the respective oligonucleotides (given 
in the table on the next page) and ligating it into pSUPER vector digested with HindIII–
BglII according to manufacturers instructions (Oligoengine). 
pSUPER-luc (Renilla luciferase)  F. Hoppe seyler 
pSUPER-18E6   F. Hoppe seyler 
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Protein target 
mRNA 
Start-end (nt) 
Oligonucleotides 
used 
h-p53 910-928 
suprp53fwd, 
suprp53rev 
hE6-AP 69-87 
suprE6APfwd, 
suprE6APrev 
hE6-AP 174-192 
suprE6AP174fwd, 
suprE6AP174rev 
hE6-AP 2421-2439 
suprE6AP2421fwd, 
suprE6AP2421rev 
hE6-AP 300-318 MD41,MD42c 
 
3.1.10 Bimolecular Fluorescence Complementation (BiFC) 
BiFC control vectors bFos.pHA.YC155 and bJun.pFLAG.YN155 and the cloning 
vectors pHA-CMV.YC155 and pFLAG-YN155 were obtained from Hu et al., 2002.  
3.1.10.1 pHA-CMV YC155 
In order to see the interaction of E6-AP and HERC2 within cells fusion constructs of 
E6-AP or RCC1B with the C-terminal fragment of YFP were generated by PCR 
amplification using the primers as given in the following table. The PCR fragment and 
pHA-CMV.YC155 vector was digested with the indicated enzymes and then the 
digested PCR fragment ligated into the digested vector using standard molecular 
biology protocols. Vectors were sequenced and confirmed for expression of the fusion 
product within cells. 
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Protein Amino acids 
Restriction 
sites (5’,3’) 
Oligonucleotides used 
RCC1b  2960-3328 EcoR I, Kpn I MD12, MD13 
E6-AP  1-852 Sal I, Kpn I MD8, MD9 
3.1.10.2 pFLAG-CMV2 YN155 
Fusion construct of RCC1B (amino acids 2960-3328) of HERC2 with the N-terminal 
fragment of YFP was generated by PCR amplification using the primers MD14 and 
MD15. The PCR fragment was digested with EcoR I and Kpn I and cloned into the 
pHA-CMV.YN155 vector. 
3.1.10.3 pcDNA3.0 YN155 constructs 
pcDNA3.0 YN155 vector was generated by PCR amplication of the YN155 fragment 
from pFLAG.CMV YN155 using primers MD28 and MD37 which contains an 
additional linker sequence and cloned into pcDNA3.0-HA. This PCR product was 
digested Hind III and Kpn I and ligated into the Hind III - Kpn I sites of pcDNA3.0.HA 
to generate pcDNA3.0. YN155HA. wt-E6-AP and inactive mutant (C820A) along with 
an N-terminal HA tag were cloned via Kpn I–Apa I restriction sites into this vector 
individually. 
3.1.10.4 pcDNA3.0 YC155 constructs 
pcDNA3.0 YC155 vector was generated by PCR amplifying the YC155 fragment from 
pFLAG.CMV.YC155 using primers MD27 and MD36 which contains as additional 
linker sequence. This PCR product was digested Hind III and Kpn I and ligated into the 
Hind III - Kpn I sites of pcDNA3.0.HA to generate pcDNA3.0 YC155. wt-E6-AP and 
inactive mutant (C820A) along with an N-terminal HA tag were cloned via Kpn I–Apa 
I restriction sites individually. 
Material and Methods 
 31
3.2 Methods 
3.2.1 Maintenance of cell lines and bacterial cultures 
3.2.1.1 Bacterial cultivation and preparation of glycerol stocks 
To maintain glycerol stocks of plasmids, the respective plasmid was transformed into 
DH5α cells and cultured overnight in LB medium containing respective antibiotic at 
37°C with shaking at 220 rpm. Glycerol stocks were prepared by mixing 150 µl of 
cooled sterile glycerol to 850 µl of overnight culture in a cryovial. The contents were 
mixed and stored at -80 °C. 
3.2.1.2 Cultivation and maintenance of mammalian cell lines 
All mammalian cell lines were incubated at 37°C under 95% humidity and 5% Carbon-
di oxide. H1299 and RKO cells were cultured in RPMI-1640 (Sigma) medium 
supplemented with 10% (vol/vol) FBS. HeLa, CaSki, SiHa, MCF-7 were cultured in 
DMEM (Sigma) medium supplemented with 10% (vol/vol) FBS. 
3.2.1.3 Freezing of cell lines in liquid nitrogen 
Approximately 70% confluent plate of the particular cell line was trypsinized. The cells 
were released from the plate with 4 ml medium and centrifuged at 1000 rpm for 2 min 
at 4° C. The cell pellet  resuspended in 2 ml freezing medium (5.9 ml growth medium, 
1.7 ml FCS, 1 ml DMSO) was aliquoted out into two cryotubes and then transferred to 
–80° C freezer. The next day the tubes were transferred to a liquid nitrogen tank. 
3.2.2 Cloning and analysis 
3.2.2.1 Purification of plasmid DNA from bacteria 
For the screening of clones, extraction of plasmid DNA from bacteria by mini-preps 
(2ml) was performed by alkaline-lysis method of Holmes and Quigley (1981).  
Plamid DNA for sequencing and transfection assays was extracted from 100ml 
bacterial cultures (midi- preps) using Macherey-Nagel AX-100 plasmid extraction kit 
according to manufacturer’s instructions 
Plasmid concentration was determined spectrophotometrically using a Bio-Rad Smart-
spec UV-spectrophotometer. 
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3.2.2.2 Polymerase chain reaction 
PCR were setup using either Pfu-polymerase (Stratagene) or Triple-Mastermix 
(Eppendorf) according to manufacturer’s instructions. 
3.2.2.3 Generation of point mutations by PCR based site directed 
mutagenesis 
Silent point mutations in E6-AP were generated using Pfu polymerase by the quick 
change site directed mutagenesis method (Stratagene). Complementary primers 
containing the required mutations were designed and PCR-amplified. The nicked 
circular PCR product was digested with Dpn I for 1 hr to get rid of the template DNA 
and 5 µl of the digest was used to transform into E.coli. 
3.2.2.4 Restriction Digestion 
Typically 30-50 µl digestion reactions were set up. All restriction enzymes were 
obtained from NEB or Invitrogen and the digestions were performed in the buffer 
systems and temperature conditions according to manufacturers’ instructions. Digestion 
were set up for 2-4hrs. 
3.2.2.5 Agarose Gel electrophoresis 
Agarose gel electrophoresis was to the method described by Sambrook et al. (1989). 
Electrophoresis was typically performed with 0.8 % (w/v) agarose gels in 1x TAE 
buffer submerged in a horizontal electrophoresis tank containing 1x TAE buffer at 1-5 
V/cm. Only for resolving fragments less than 1,000 bp, 1-2% (w/v) agarose gels in 1x 
TAE buffer were used. Gels were analyzed under a UV Tran illuminator and 
photographed using Gel documentation system (from Fuji or MWG biotech) 
3.2.2.6 Purification of DNA fragments and PCR products from 
Agarose gels 
DNA fragments from restriction digestion or from PCR reactions were separated by 
agarose gel electrophoresis. The gel piece containing the desired DNA fragment was 
carefully excised while observing the ethidium bromide stained gel under a UV Tran 
illuminator. The DNA fragment was then purified from the excised gel piece using the 
Qiagen gel extraction kit according to manufacturer’s instructions. 
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3.2.2.7 Ligation 
Ligations were set up in 20µl reactions at room temperature for 2hrs. For PCR cloning, 
the digested PCR product and the appropriate linearized plasmid were mixed in a 
equimolar ratio of 1:3. T4 DNA ligase (Gibco) was added according to manufacturers 
instructions. In addition, 1µl of 0.1M DTT was added. For cloning of sh-RNA 
constructs, dephosporylated vector and annealed and phosphorylated oligonucleotides 
were used in ligation reactions.  
3.2.2.8 Transformation by CaCl2 method 
Plasmid DNA (5 µl of a ligase reaction or ~100 ng of a purified plasmid) was mixed 
with 100-200 µl of CaCl2 -competent E.coli cells and incubated on ice for 30 min. The 
cells were heat-shocked at 42ºC for 60-90s and immediately transferred to ice for 5 
minutes. 1 ml of pre-warmed (at 37ºC) SOC medium was added to the above tube and 
incubated at 37ºC with shaking for 1 hr. Finally, the transformation mix, or an 
appropriate dilution, was plated onto selection plates and the transformants were 
allowed to grow overnight at 37ºC. 
3.2.2.9 Estimation of DNA concentration 
Concentration of purified plasmid DNA was estimated using a UV spectrophotometer. 
(Biorad Smart spec Plus). Measurements were performed in quartz cuvettes using the 
standard 1O.D280 1.0 = 50µg/ml DNA. The ratio O.D260/OD280 was determined to 
assess the purity of the sample. 
3.2.3 Transfection of mammalian cell lines 
Cells were either transfected for transient assays or for generation of stable cell lines 
using either Lipofectamine 2000 (Invitrogen) (3.2.3.1) or DOTAP (Roche) (3.2.3.2). In 
transient transfections, transfection efficiency was normalized by co-transfecting 200ng 
of an expression construct expressing β-galactosidase (pRc/CMV-β gal).  
To generate stable cell lines, cells were transfected like transient transfection, but 
however in the absence of pRC/CMV- β gal construct. For constructs lacking a 
selection marker, a vector encoding a resistance marker was cotransfected at a ratio of 
1:10. 24 hrs after transfection, the cells were trypsinized and plated onto a larger plate 
(e.g. from 6cm plate to 10cm plate) 24 hrs after transfection. One day later, selection 
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was started with the respective antibiotic. Prior to this, the amount of antibiotic required 
for selection was optimized for each cell line. The optimized amount of antibiotic 
required is tabulated in Table 4 and Table 5. 
cell line concentration (mg/ml) 
H1299 1 
SiHa 1.6 
HeLa 0.7 
CaSki 0.7 
C33-A 0.7 
Table 4: Concentration of Geneticin used for the selection of stable colonies in 
various cell lines 
3.2.3.1 Transfection using Lipofectamine 2000 
Cells were transfected by lipofection using Lipofectamine 2000 (Invitrogen) according 
to manufacturer’s instructions. One day before transfection cells were seeded onto a 6 
cm plates such that they were 90% confluent on the day of transfection. For 
transfections in H1299 cells the total amount of plasmid DNA was maintained at 2µg 
and was transfected using 4µl of Lipofectamine 2000 reagent. For transfection of HeLa 
and SiHa cell lines, the amount of Lipofectamine 2000 to DNA ratio was maintained at 
a ratio of 1:1 (µg/µl).  
3.2.3.2 Transfection using DOTAP 
Cells were seeded onto a 6cm plate 24 hrs prior to transfection such that they were 50-
70% on the day of transfection. For each transfection in a 6cm plate, 2µg of total 
plasmid DNA was suspended in HBS and was added to 14µl of DOTAP (Roche) and 
DNA-liposomal complexes were allowed to form by incubating for 10 min. 
Meanwhile, the medium from the plates was replaced with DMEM without FBS. DNA-
Liposomal complexes formed were added to the cells and incubated at standard growth 
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conditions. The medium was replaced with normal growth medium containing FBS 4 
hrs later. Cells were lysed after the indicated time point. 
3.2.4 Protein studies 
3.2.4.1 Lysis of transfected cells 
At indicated time points after transfection, the monolayer of cells was washed thrice 
with cold PBS. The cells were scraped into 500 µl PBS from the plates using a plastic 
scraper and pelleted down. The pellet was lysed in 100 µl TNN lysis buffer on ice for 
20 min and centrifuged at 13,200 rpm for 30 min to remove cell debris. The supernatant 
was carefully removed. For transient assay, sample loadings were normalized by β 
galactosidase assay (3.2.4.3). For stable transfections and siRNA transfection protein 
loading was normalized by Bradford assay.  
3.2.4.2 Normalization of sample loading /Protein Estimation 
3.2.4.3  β-galactosidase assay 
To a 96 well plate kept on ice, 120µl of buffer Z was added per well. To this 10µl of 
cell lysate and 5µl of ONPG (Orthonitrophrnyl-β-D-galactopyranoside, concentration: 
4mg/ml in 100mM NAH2PO4 pH 7.4) was pipetted and mixed. The plate was incubated 
at 37° C till yellow color developed (approx 20 min) and the absorbance was measured 
at λ410 in an ELISA reader. All estimations were done in duplicates.  
3.2.4.4 Bradford assay 
Normalization of total protein amounts was performed using Bio-rad Bradford reagent. 
5µl of protein lysates was added to 795 µl of milli Q water. 200µl of reagent was added 
and reading was taken after 5 min at λ595 using a Bio-Rad spectrophotometer 3000. 
3.2.4.5 SDS-Poly Acrylamide Gel Electrophoresis (SDS-PAGE) 
SDS-PAGE analysis was done according to the protocol of Laemmli (1970). For 
analysis of p53, 10% separating gels were used and for the analysis of Hdm2, E6-AP, 
8% separating gels were used. Protein loadings were normalized by β-galactosidase 
analysis or by Bradford assay. Normalized samples were boiled for 5-10 min at 100° C 
in Laemmli loading buffer prior to loading onto the gels. The gels were electrophoresed 
at constant current setting of 44mA (for 1 gel) or 80mA (for 2 gels) for 200min. 
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3.2.4.6 Immunoprecipitation 
Cell lysates were prepared in TNN lysis buffer (3.2.4.1) and protein amounts were 
normalized by Bradford assay (3.2.4.4). The normalized amounts of cell lysates was 
precleared with 50 µl of protein A sepharose slurry (1:1 ratio of Protein A sepharose 
bead: TNN lysis buffer) by incubating at 4°C with rotation for 1 hr. Samples were then 
centrifuged and to the supernatant 1µl of monoclonal E6-AP antibody was added and 
incubated for 1hr at 4°C with rotation. 50µl of Protein A sepharose slurry was added 
and the samples were further incubated at 4°C overnight. The Protein A sepharose 
beads were washed four times with TNN lysis buffer and to the beads 50µl of 2X 
Laemmli loading buffer was added. Samples were boiled at 100°C for 5 min, 
centrifuged and the supernatant was analyzed by SDS-PAGE. 
3.2.4.7 Western Blot and ECL 
Protein samples were separated by SDS-PAGE and the gel was incubated in Transfer 
buffer. Required size of PVDF membrane (Millipore) was cut and activated by 
incubating the membrane in Methanol for 10 sec. The membrane was then incubated in 
transfer buffer. Western blotting was performed using a wet transfer apparatus (BIO-
RAD) for 150 min at 40V. After transfer, the membrane was blocked with 5%(w/v) 
milk solution in TNE-T for 1hr at RT. The membrane was washed and incubated in 
Primary antibody for one hour. After washing the membrane with TNE-T for one hour 
(5 times, 10 min each), the membrane was incubated with secondary antibody 
conjugated with horse radish peroxidase. The membrane was washed once again for 1 
hr with TNE-T the membrane was developed using ECL (Enhanced 
Chemiluminescence) kit (Amersham) according to manufacturer’s instructions.  
3.2.5 Bimolecular Flourescence Complementation (BiFC) 
Cells were grown in 24 well plates on coverslips and transfected with 500 ng each of 
the indicated complementing BiFC vectors using lipofectamine 2000 (3.2.3.1). To 
measure transfection efficiency in parallel 1µg of YFP expressing vector was also 
transfected. 16-24 hrs later the transfected cells were shifted to 30°c for fluorescence 
maturation. The cells were initially observed for fluorescence using a Nikon inverted 
microscope and then fixed using either methanol or 4% Para formaldehyde. Fixed cells 
were stained with DAPI and mounted onto glass slides using gelvatol (3.2.7.6). Images 
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were taken using an Olympus IX70 inverse microscope equipped with a 40X LCPlanFI 
0.6 objective. Images were captured either with a JAI CV-M10 CCD video camera or a 
SensiCam cooled CCD video camera. Images were false colored using Adobe 
Photoshop software. 
3.2.6 RNA interference 
3.2.6.1  siRNA/shRNA design 
siRNA/shRNA targeting sequences were identified using the following RNAi-design 
software freely available on the internet: Oligoengine ver-1.1(www.oligoengine.com), 
Dharmacon siRNA design center (www.Dharmacon.com), siDesign tool 
(www.mwgbiotech.com). All siRNA sequences were BLAST searched in the National 
Center for Biotechnology Information’s (NCBI) ‘‘search for short nearly exact 
matches’’ mode against all human sequences deposited in the GenBank and RefSeq 
databases. Sequences which did not have significant homology to genes other than the 
targets were chosen and synthesized at Dharmacon, USA or MWG-Biotech AG, 
Germany (3.1.9.1).  
3.2.6.2 Transfection of synthetic siRNA 
One day prior to transfection, cells were seeded onto sterile coverslips (3.2.7.1) such 
that they were 30-50% confluent at the time of transfection. A final siRNA 
concentration of 100nM was transfected using Oligofectamine according to the 
protocol of Tuschl and coworkers (Elbashir et al., 2001). For each transfection per well 
(24 well cell culture plate), 3µl (60 pmol) of 20µM stock siRNA was diluted in 50 µl of 
Opti-MEM
® 
I Reduced Serum Medium (Gibco) in a sterile polypropylene tube and 
mixed gently. In a separate tube, 3µl of Oligofectamine (Invitrogen) was added to 12 µl 
of Opti-MEM
® 
I Medium, mixed gently and incubated for 5 minutes at room 
temperature. The diluted siRNA and Oligofectamine were gently mixed together and 
incubated at room temperature for 20 min. Meanwhile, the adherent cells (on the 
coverslips) were washed once with Optimem I and replaced with 500µl of Optimem I. 
The siRNA-Oligofectamine Mixture was added drop wise to the cells and incubated at 
37°C. After 4hrs, 300µl of three fold FBS containing medium was added to the cells 
and incubated for the desired period until analysis.  
Material and Methods 
 38
For comparison of the parental HeLa versus the p53 null clones (A1 and C2 clones), 
20µM of E6-AP siRNA was taken while the final concentration of siRNA was 
maintained at 100nM by diluting with siRNA for renilla luciferase (si-control). 
3.2.6.3 Estimation of siRNA transfection efficiency 
To estimate the transfection efficiency of synthetic siRNA in various cell lines, cells 
were seeded onto coverslips in 24 well plates (3.2.7.1). 3µl (stock solution: 30mg/ml in 
water) of FITC-Dextran (SIGMA) was transfected using oligofectamine in place of 
siRNA (3.2.6.2). As a negative control, cells were mock transfected with FITC-Dextran 
minus Oligofectamine. Care was taken to minimize exposure to light to prevent photo 
bleaching. 24 hrs later, the coverslips were stained by DAPI and mounted onto glass 
slides (3.2.7.6). Images were taken using and inverse microscope using appropriate 
filters (3.2.8). 
As an alternative to FITC-dextran, labeled siRNA (Negative control siRNA Alexa 555, 
Qiagen GmBH, Germany) was also used to estimate transfection efficiency. 
3.2.7 TUNEL (Tdt mediated dUTP nick end labeling) assay and 
Immunofluorescence 
3.2.7.1 Seeding of cells onto coverslips 
12 mm-diameter coverslips were sterilized by soaking in absolute ethanol for 15 
minutes, removed, and allowed to dry. Single coverslips were aseptically placed into 
each well of a 24 well plate (Greiner) and cells seeded according to required confluency 
and synthetic siRNA was transfected .according as given in 3.2.6.2 
3.2.7.2  Fixation using 4% paraformaldehyde  
At indicated time points, the coverslips containing the transfected cells were carefully 
transferred to a new 24 well plate making sure that the adherent cells faced upwards. 
The coverslips were washed twice with 500µl of PBS containing 100mM of Mgcl2. 
500 µl of freshly prepared 4% Para formaldehyde solution was added carefully into 
each well and incubated at room temperature for 1 hr. The coverslips were washed 
twice with PBS and further processed for immunofluorescence (3.2.7.3) or were stored 
in PBS at 4°C. 
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3.2.7.3 Permeabilization of fixed cells 
Prior to immunolabelling and TUNEL reaction the PBS was removed from the fixed 
cells (3.2.7.2) and permeabilised using 500µl of freshly prepared 0.1% Triton X-100 in 
0.1% sodium citrate for 2 minutes on ice. After permeabilization the coverslips were 
washed twice with PBS.  
3.2.7.4 TUNEL reaction  
The permeabilized coverslips containing the fixed cells were transferred from the 24 
well plates to a humidified chamber (an opaque humidified box in which parafilm 
pieces are fixed onto glass slides) making sure that the permeabilized cells face 
upwards. TUNEL reaction was performed using the in situ cell death detection kit 
(Roche Diagnostics GmbH, Germany) according to manufacturer’s instructions. In 
brief, 5µl TUNEL–enzyme was mixed with 45 µl of TUNEL-label solution to obtain 
50µl TUNEL-reaction mixture per coverslip. The TUNEL-reaction mixture was added 
carefully onto each coverslip and overlaid with another coverslip to prevent evaporative 
loss. The humidified chamber was incubated at 37° C in the dark for 1 hr. The 
overlaying coverslip was removed and the coverslip containing the cell sample was 
washed three times with PBS and then processed for immunolabelling. During the 
subsequent steps excessive exposure to light was avoided to prevent photo bleaching of 
the label. 
3.2.7.5 Immunolabelling for p53 
To each coverslip containing the fixed cells 180 µl of primary antibody (polyclonal 
anti-p53 antibody in PBS containing 1% BSA, dilution 1:200) were incubated at room 
temperature for 1 hr. After incubation, the excess unattached antibody was removed by 
washing the coverslips 4 times with PBS. Excess PBS was removed and the coverslip 
was incubated with 180 µl of secondary antibody for 1 hr in dark (Alexa Fluor 568 goat 
anti rabbit IgG, Molecular probes, dilution 1:1000 in pBS containing 1% BSA). 
Following this incubation, the coverslip was once again washed 4 times with PBS and 
processed for DAPI staining. 
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3.2.7.6  DAPI (4’, 6 diamidino-2-phenylindole) staining and mounting 
onto glass slides 
To visualize the nuclei of the cells, coverslips were incubated with 200 µl DAPI 
(Molecular Probes) at a final concentration of 300 nM in PBS for 15 min. The 
coverslips were washed with PBS thrice, rinsed with water, ethanol, and air dried. The 
coverslip was mounted onto a glass slide using Gelvatol. The coverslips was allowed to 
solidify and observed by fluorescence microscopy (3.2.8).  
3.2.8 Microscopy 
Immunofluorescence images were taken using an Olympus IX70 inverse microscope 
equipped with a 40X LCPlanFI 0.6 objective. Images were captured either with a JAI 
CV-M10 CCD video camera or a SensiCam cooled CCD video camera. Images were 
false colored using Adobe Photoshop software. 
3.2.9 Relative quantitative reverse transcription PCR analysis 
3.2.9.1 Isolation of total RNA  
Cells were grown in 6cm-diameter plates and transfected with synthetic siRNA (3.2.6.2 
48 hrs post-transfection total RNA was isolated by Trizol method using Trizol reagent 
(Invitrogen) according to manufacturer’s instructions. Isolated RNA was dissolved in 
10-20µl of RNase free water and quantitated using a UV-spectrophotometer (Bio-Rad). 
3.2.9.2 First strand synthesis 
First strand cDNA synthesis was performed using random hexamers (Invitrogen) and 
5µg of total RNA. Reverse transcription was performed using Superscript II RT 
(Invitrogen) according to manufacturer’s instruction.  
3.2.9.3 Quantitation of mRNA knockdown 
 Relative quantitative RT-PCR analysis was performed using the QuantumRNATM 18S 
Internal Standard kit (Ambion, Austin,USA). For amplification of E6-AP specific 
products, primers MD10 and UK13 were utilized which yields a 750bp product and 
recognizes all known isoforms of E6-AP. In each amplification reaction, the 18S rRNA 
PCR primer/competimer pairs were included as an internal standard at a ratio of 1:9. 
25µl PCR reactions were set up and separated on a 1.5% agarose gel. The gel was 
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stained after separation with Ethidium bromide and photographed using a FUJI imaging 
system (LAS 3000). Signal intensities were quantitated using AIDA imaging analyzer 
software ver 4.06 and fold change was calculated.  
3.2.9.4 Immunoprecipitation and western blot analysis of RNAi 
treated cells 
For IP and western analysis cells were seeded onto 6cm plates the previous day such 
that they are 30%-50% confluent at the time of transfection. 100nM of siRNA was 
transfected as in the case for immunofluorescence analysis. Immunoprecipitation was 
carried out as described under 3.2.4.6. 
3.2.10 Generation of stable cell lines  
3.2.10.1 Generation of stable cell lines ectopically expressing E6-
AP or E6-AP deletion mutants 
To generate stable cell lines ectopically expressing E6-AP or E6-AP deletion mutants, 
cells were transfected using liposomal transfection reagents DOTAP or Lipofectamine 
2000. For DOTAP transfection, 2µg of the HA-tagged pEF constructs of Wt E6-AP, 
∆N30 or E6-AP∆E6 was transfected using 14µl of DOTAP on a 6cm plate as described 
in 3.2.3.2. For Lipofectamine 2000 transfection 2µg of the respective construct was 
transfected using 2µl of Lipofectamine 2000 in a 6 cm plate as described in 3.2.3.1. 24 
hrs post-transfection, cells were split onto two 10cm plates. The next day, the medium 
was replaced with selection medium (see Table 4) for amount of G418 antibiotic 
employed for each cell line). Pooled stable clones were selected for around 4 weeks, 
and checked for overexpression as soon as sufficient cells were available for analysis. 
In parallel, aliquots of the pooled stable cell lines were frozen down in liquid nitrogen 
(3.2.1.3). 
3.2.10.2 Generation of stable p53 null single cell clonal cell lines  
HeLa and SiHa cell lines were seeded 24 hrs before transfection onto 6 cm –diameter 
plates such that they were 90% confluent on the day of transfection. Cells were co-
transfected with pSUPER-p53 and a vector encoding a neomycin resistance gene 
(pEF1/V5-His) in a ratio of 1:10 respectively (total DNA transfected 2µg) using 
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Lipofectamine 2000 (3.2.3.1). The next day cells were trypsinized and plated onto a 10 
cm plate. Colonies expressing Neomycin resistance were selected for using Geneticin 
(G418) for a period of 10-15 days. Cells were trypsinized, counted and plated onto 96 
well plates such that each well contained only a single cell. Clones were allowed to 
grow under selection pressure till sufficient amount of cells were obtained for analysis. 
Knockdown efficiency was confirmed by western blot analysis (3.2.4.7) and cell lines 
frozen down. 
3.2.11 Colony reduction assay  
HeLa and SiHa cells were seeded on a 24 well plate such that they were 90% confluent 
at the time of transfection. 1µg of indicated pRetroSUPER vector DNA was transfected 
using 1µl Lipofectamine 2000 reagent (3.2.3.1). The next day cells were trypsinized 
and plated onto a 6cm cell culture plate. 24 hrs later the medium was replaced with 
selection medium containing the puromycin (Table 5). Medium was changed every 
three days. After 15-20 days, the plates were washed twice with PBS and stained with 
crystal violet for 15 minutes. The plates were washed with deionised water and allowed 
to dry. Scanned Images of the plates were taken using a Mustek P3600 A3 Pro Scanner. 
Cell line Puromycin final concentration (µg/ml) 
HeLa 4.0 
SiHa 2.0 
H1299 4.0 
MCF-7 4.0 
Table 5: Concentration of puromycin used for selection of mammalian cells 
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4. Results 
4.1 Identification of potent siRNA/shRNA sequences that target E6-
AP mRNA 
4.1.1 siRNA/shRNA design 
In order to characterize the physiological role of E6-AP by RNA interference, both 
chemically synthesized small interfering RNA (siRNA) of 21 nucleotides (Elbashir et 
al., 2001) and DNA-based short hairpin RNA expression vectors (shRNA) were 
employed (Brummelkamp et al., 2002b). Although a number of computational 
programs have been developed to identify potent siRNA/shRNA targets, not all 
siRNA/shRNAs designed against a particular mRNA are functionally efficient. Hence, 
four different siRNA/shRNA target sequences (Table 6), specifically targeting E6-AP 
were identified using RNAi-design software (see Materials and Methods, 3.2.6.1). In 
the course of identifying siRNA/shRNA target sequences, sequences which target all 
known E6-AP isoforms were chosen. Figure 7A depicts the genomic organization of 
E6-AP. The isoforms of E6-AP and the regions where the siRNA/shRNAs target the 
various transcripts are indicated in Figure 7B. The siRNA/shRNA target sequences are 
numbered based on the first nucleotide of the target sequence (wherein nucleotide 1 
corresponds to the first A of the start codon of isoform I). 
siRNA/shRNA Targeting sequence in E6-AP 
shRNA-69 (sh-E6-AP1) and si-E6-AP1 UGA AGC CUG CAC GAA UGA G 
shRNA-174 ACU CUG UGA UCC UCA UCC C 
shRNA-2421 UGG CCC AGA CAC AGA AAG G 
shRNA-300 (sh-E6-AP2) and si-E6-AP2 AGA UGU GAC UUA CUU AAC A 
Table 6: siRNA/shRNA targeting sequence in E6-AP. To generate shRNA vectors targeting 
E6-AP, sense and antisense oligonucleotides containing the targeting sequence and a nine 
nucleotide loop were annealed and cloned. siRNAs against E6-AP were generated by 
synthesizing sense and antisense strands of the targeting sequence with two nucleotide dT 
overhang at the 3’end. These were either purchased as annealed oligos or were annealed 
according to manufacturer’s instructions (Material and Methods, 3.1.9.1). Note that the 
shRNA-69 (sh-E6-AP1) and si-E6-AP1 target the same sequence in E6-AP. Similarly, shRNA-
300 (sh-E6-AP2) and si-E6-AP2) target the same sequence (see text for details). 
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Figure 7: Schematic representation of the splice variants of E6-AP and the 
location of the siRNA/shRNA targeting sequences. A. UBE3A genomic structure. The 
UBE3A gene has the potential to encode five mRNA subtypes coding for three protein isoforms 
of E6-AP (isoforms I, II and III). Exons are indicated by closed boxes, and the coding regions 
are indicated by pink boxes. The dark colored boxes correspond to the exons which are present 
specifically in Isoform II (exon 5) and isoform III (exon 4) respectively (exons are numbered as 
reported in Kishino and Wagstaff, 1998). The position of translation initiation codon is 
indicated by asterisks B. Splicing pattern of mRNAs and corresponding location of the 
siRNA/shRNA targeting sequences. The exons present in subtypes-1, 2, and 3 (representing 
protein isoforms I, II and III respectively) are indicated (not drawn to scale). Position of 
siRNA/shRNA targeting sequences in the three isoforms is depicted below as a small dash. 
siRNA/shRNA target sequences are numbered by the first nucleotide of the target sequence 
(according to isoform I) . Note: subtype 4 and 5 of E6-AP which encodes isoform I are not 
shown in figure. 
4.1.2 Evaluation of the silencing potency of different shRNAs 
specific against E6-AP mRNA 
To evaluate the silencing potency of the identified shRNA, vectors (pSUPER) with the 
above target sequences were generated. These vectors (namely shRNA-69, shRNA-
174, shRNA-2421, and shRNA-300) were individually co-transfected with an 
expression vector encoding an HA-tagged form of E6-AP isoform I (HA-E6-AP) and a 
vector expressing a puromycin resistance gene (pCMV.puro) into H1299 cells. A 
shRNA vector targeting renilla luciferase was used as negative control (sh-control). To 
select for transfected cells, the cells were subjected to puromycin selection and 
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silencing of ectopically expressed E6-AP was determined 96 hr post-transfection by 
western blot analysis using an anti-HA antibody (Figure 8). Relative comparison of the 
efficiency of knockdown indicated that the shRNA-69 (hence forth referred to as sh-
E6-AP1) and shRNA-300 (hence forth referred to as sh-E6-AP2) gave efficient 
silencing greater than 55% on the protein level and was used in further experiments. 
 
Figure 8: Evaluation of the silencing potency of different shRNAs specifically 
targeting E6-AP. A. Down-regulation of ectopically expressed E6-AP in H1299 cells. HA 
tagged wild type E6-AP (HA-E6-AP) and shRNA vectors specifically targeting E6-AP were 
co-transfected into H1299 cells along with a vector expressing the puromycin resistance gene 
as indicated. As a negative control shRNA vector targeting renilla luciferase (control) was used. 
Transfected cells were selected with puromycin and analyzed by western blotting with anti-HA 
antibody. Relative percentage of knockdown was quantified using AIDA imaging software. 
Relative knockdown values are the average of 2 independent experiments.  
Identical targeting sequences as that of sh-E6-AP1 and sh-E6-AP2 were used for 
chemical synthesis of siRNA of 21 nts (hence forth referred to as si-E6-AP1 and si-E6-
AP2 respectively). As a negative control sequence targeting renilla luciferase (si-
control) was also synthesized. In case of synthetic siRNA, transfection efficiencies 
greater than 90% can be achieved in most cell lines (Figure 24 and data not shown) and 
hence were used for transient transfection studies. 
4.2 Down-regulation of E6-AP in HPV-positive cell lines by RNAi 
4.2.1  Down-regulation of E6-AP has a growth-suppressive effect in 
HPV-positive cell lines 
It is known that the E6 oncoprotein recruits the cellular ubiquitin-ligase E6-AP to target 
p53 for degradation and that continuous expression of E6 is required for the 
maintenance of the malignant phenotype of HPV-positive cancer cells (zur Hausen, 
2000; 2002). Indeed interference with E6 expression or E6 activity results in growth 
suppression, which is accompanied by significant increase in p53 levels and apoptosis 
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in HPV-positive cell lines (Butz et al., 2000; Butz et al., 2003). Similarly down-
regulation of E6-AP expression by antisense approaches or overexpression of a 
catalytically inactive E6-AP mutant results in the accumulation of p53 in HPV-positive 
cells but not in HPV-negative cells (Beer-Romero et al., 1997; Talis et al., 1998). 
Furthermore, ribozyme-mediated reduction of E6-AP expression enhances the 
apoptotic response of HeLa cells , an HPV-18-positive cell line, to the DNA damage-
inducing drug mitomycin C (Kim et al., 2003). 
 
 
Figure 9: Down-regulation of E6-AP has a growth suppressive effect in HPV-18E6 
positive HeLa cell line. A. Phase contrast images of siRNA treated HeLa cells. 100nM 
synthetic siRNA specific against renilla luciferase (si-control) or E6-AP (si-E6-AP1, siE6-AP2) 
were transfected into HeLa cells seeded in a 24 well plate and monitored for 4 days. Phase 
contrast images on day 1 and day 4 post-transfection were taken. B. Western blot analysis of 
E6-AP down-regulation. HeLa cells were transfected on a 6 well plate with respective siRNA 
and lysed 48 hrs post-transfection (Material and methods, 3.2.4.1). Western blot analysis was 
performed using anti-E6-AP monoclonal antibody. Arrow marks indicate the running position 
of E6-AP. C. Relative quantitative reverse transcription PCR analysis. Silencing of E6-AP 
mRNA was determined at 48hrs post-transfection by isolating total mRNA from siRNA treated 
cells. Relative quantitative reverse transcription PCR analysis was performed using E6-AP 
specific primers which results in a 750 bp amplification product. As an internal standard, 18s 
rRNA was amplified (488bp product). 
To determine if down-regulation of E6-AP expression by RNAi has any effect on cell 
growth, HPV-18E6 positive HeLa cells were transfected in a 24 well plate with siRNAs 
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directed either against renilla luciferase (si-control) or E6-AP (si-E6-AP1 and si-E6-
AP2) and monitored. In comparison to si-control treated cells, cells treated with si-E6-
AP1 showed signs of growth suppression starting from day 2-3 and by day 4, 
significant differences in cell viability were observed under the conditions used (Figure 
9A). While treatment with si-E6-AP1 resulted in growth suppression with only 3-5 
percent of cells remaining at day 4, si-E6-AP2 interfered less efficiently with viability 
with 15-20 percent remaining day 5-6 post-transfection (data not shown and see 
Discussion, 5.1).  
 
Figure 10: Down-regulation 
of E6-AP has a growth 
suppressive effect in HPV-
16E6 positive SiHa cell line. 
Phase contrast microscopy of 
siRNA treated HeLa cells. 100nM 
synthetic siRNA specific against 
renilla luciferase (si-control) or 
E6-AP (si-E6-AP1, siE6-AP2) 
were transfected into SiHa cells 
seeded in a 24 well plate and 
monitored for 4 days. Phase 
contrast images were taken on day 
1 and day 4 post-transfection. 
 
To obtain evidence that the observed growth suppression correlated with E6-AP 
silencing, the transfection was scaled up to a 3.5 cm cell culture plate and silencing of 
E6-AP mRNA and protein expression were assessed. For protein analysis, cells were 
lysed 48 hrs post-transfection and Western blot analysis was performed using anti-E6-
AP antibody (Figure 9B). A 45-70% decrease in E6-AP protein levels was observed 
with si-E6-AP1 and si-E6-AP2, respectively. For estimating mRNA down-regulation, 
total RNA was isolated from cells transfected with control or E6-AP specific siRNA 48 
hrs post-transfection. A relative quantitative reverse transcription (RT) PCR analysis 
was performed using E6-AP specific primers (Material and Methods, 3.2.9). As an 
internal standard, primers against 18S rRNA were used and amplified along with E6-
AP. Relative quantification indicated that mRNA levels was down-regulated by 
approximately 2-3 fold (Figure 9C). 
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To extrapolate the growth suppressive effect of E6-AP down-regulation, to other high-
risk HPV infected cell lines, similar experiments were performed in HPV-16 positive 
SiHa cells. As shown in Figure 10, cells treated with E6-AP specific siRNA 
significantly inhibited their growth, too. 
4.2.2 Down-regulation of E6-AP expression by RNA interference 
induces accumulation of p53 and interferes with the viability 
of HPV-positive cancer cell lines 
Activation of the p53 dependent pathway has been linked to the accumulation of the 
p53 protein and its increased transcriptional activity (Harris and Levine, 2005). As 
mentioned earlier, down-regulation of E6-AP using antisense, ribozyme or catalytical 
inactive forms of E6-AP results in accumulation of p53 (Beer-Romero et al., 1997; 
Talis et al., 1998; Kim et al., 2003). To correlate the growth suppressive effect 
observed upon down-regulation of E6-AP by RNAi, cellular p53 levels were visualized 
by immunofluorescence analysis in HeLa cells. siRNAs specifically targeting the 
expression of either E6-AP (si-E6-AP1 or si-E6-AP2), renilla luciferase (si-control) or 
Hdm2 (si-Hdm2) were transfected into HeLa cells and immuno-stained for p53 at 24 
hrs (day 1) and 96 hrs (day 4) post-transfection (Figure 11A) (Material and methods, 
3.2.7.5). Transfection of si-control or si-Hdm2 into HeLa cells did not show any 
increase in p53 levels or effect on cell viability, supporting the notion that Hdm2 plays 
no role or only a minor role in p53 degradation in HPV-positive cells (Hengstermann et 
al., 2001). However, transfection of si-E6-AP1 or si-E6-AP2 showed significantly 
increased levels of p53. This increase in p53 levels was determined by Western blot 
analysis (Figure 11B). 
Since one of the consequences of p53 stabilization results in induction of apoptosis, 
TUNEL (TdT-mediated dUTP biotin nick end labelling) analysis was performed at day 
1 and day 4 post-transfection (Material and Methods, 3.2.7). Whereas cells treated with 
control or Hdm2 specific siRNA were negative for TUNEL staining, most of the HeLa 
cells transfected with si-E6-AP1 were positive for apoptosis at day 4. In comparison to 
si-E6-AP1 transfected cells, only few of the si-E6-AP2 treated cells showed signs of 
apoptosis at day 4 (Figure 11B and see Discussion). 
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Figure 11: Down-regulation of E6-AP expression by RNAi induces accumulation 
of p53 and interferes with the viability of HeLa cells. A. Immunofluorescence analysis 
of HeLa cells treated with siRNA. Synthetic siRNAs specific for E6-AP (si-E6-AP1 and si-
E6AP2), Hdm2 (si-Hdm2), and renilla luciferase (si-control) were transfected into HeLa cells 
seeded on coverslips in 24 well plates. Cells were fixed on day 1 and day 4 post-transfection 
and levels of p53 (p53) and induction of apoptosis (TUNEL) were determined by 
immunofluorescence and TUNEL assay (TdT-mediated dUTP-biotin nick end labeling) 
respectively. In addition, cells were nuclei stained using DAPI (4’,6-diamidino-2-
phenylindole). B. Silencing of E6-AP expression leads to accumulation of p53. HeLa cells were 
transfected on a 6 well plate with indicated siRNA and lysed 48 hrs post-transfection. Western 
blot analysis was performed using anti-p53 DO-1 monoclonal antibody. 
A similar experiment was also performed in HPV-16-positive SiHa cell line (Figure 
12A). As in the case of HeLa cells, an apoptotic response was also observed in SiHa 
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cells treated with E6-AP specific siRNA (data not shown for si-E6-AP2), whereas no 
signs of growth suppression or apoptosis were seen with either si-Hdm2 or si-control 
treated cells. Parallel to these experiments, the efficiency of silencing was confirmed by 
western blot analysis (Figure 12B and C). 
 
Figure 12: Down-regulation of E6-AP expression by RNAi induces accumulation 
of p53 and interferes with the viability of SiHa cells. A. Immunofluorescence analysis 
of SiHa cells treated with siRNA. Synthetic siRNAs specific for E6-AP (si-E6-AP1), Hdm2 (si-
Hdm2), or renilla luciferase (si-control) were transfected into SiHa cells seeded on coverslips in 
a 24 well plate. Cells were fixed on day 1 and day 4 post-transfection and levels of p53 (p53) 
and induction of apoptosis (TUNEL) were determined by immunofluorescence and TUNEL 
assay (TdT-mediated dUTP-biotin nick end labeling) respectively. In addition, cells were 
visualized by phase-contrast microscopy (PC) and nuclei were stained by DAPI (4’, 6-
diamidino-2-phenylindole). B and C. SiHa cells were transfected with siRNA as indicated 
siRNA and lysed 48 hrs post-transfection. Western blot analysis was performed using anti-E6-
AP monoclonal antibody (B) or anti-Hdm2 monoclonal antibody (C). 
To further confirm this growth suppressive phenotype, a shRNA retroviral vector 
system called pRetroSUPER (pRS) was used. This vector contains the shRNA 
expression cassette along with a puromycin resistant gene and can be used for short 
Results  
 51
term and long term assays using DNA transfection or retroviral transduction (Berns et 
al., 2004). Using this vector system, colony formation assays were performed in HeLa 
and SiHa cell lines (Materials and Methods, 3.2.6.3). As shown in Figure 13, colony 
formation assays performed by transfection of pRS-sh-E6-AP1 or pRS-sh-E6-AP2 led 
to significant decrease in colony numbers in comparison to pRS-sh-control. Of the 
surviving colonies that appeared on the E6-AP knock down plates showed no 
significant decrease in E6-AP expression indicating that E6-AP was not down-
regulated in these colonies (data not shown). 
 
Figure 13: Colony formation assay of E6-AP down regulation in HeLa and SiHa 
cell lines. HeLa (A.) and SiHa (B.) cell lines were seeded on a 24 well plate and transfected 
with the indicated vectors targeting renilla luciferase (pRS-sh-control) or E6-AP (pRS-sh-E6-
AP1 and pRS-sh-E6-AP2). 24 hrs later, cells were trypsinzed and plated onto a 6cm plate. 
Colonies were selected for with puromycin and stained after 10-15 days. 
The data presented above indicates that a certain threshold level of E6-AP expression is 
required for viability of HPV-positive cervical cancer cell lines and that down-
regulation of E6-AP expression results in p53 accumulation and induction of apoptosis. 
However, since E6-AP is a cellular protein that is expressed in all cell lines tested 
regardless of their HPV status, the anti-growth-suppressive properties of E6-AP may 
not be related to its ability to interact with E6 and target p53 for degradation. 
4.3 Down-regulation of E6-AP in HPV-negative cell lines 
4.3.1 RNAi induced down-regulation of E6-AP expression has no 
growth suppressive effect in HPV-negative tumour cell lines 
under transient conditions 
To determine whether down-regulation of E6-AP has a growth suppressive effect in 
HPV-negative cells, cell lines expressing wild-type p53 (i.e. MCF-7, RKO and U2OS) 
were transfected with siRNA specific against E6-AP (si-E6-AP1 and si-E6-AP2), 
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Hdm2 (si-Hdm2), or renilla luciferase (si-control). As reported previously (Linares et 
al., 2003), down-regulation of Hdm2 resulted in p53 accumulation and induction of 
apoptosis. However, no indication for p53 accumulation and/or interference with cell 
viability was observed upon treatment of the cells with E6-AP-specific siRNA (Figure 
14 and data not shown). 
 
Figure 14: Down-regulation of E6-AP does not affect growth or p53 levels in HPV-
negative cell line MCF7. Synthetic siRNAs against E6-AP (si-E6-AP1), renilla luciferase 
(si-control), and Hdm2 (si-Hdm2) were transfected into HPV-negative cell line, MCF-7. Levels 
of p53 and induction of apoptosis were determined by immunofluorescence and TUNEL assay 
(TdT-mediated dUTP-biotin nick end labeling) respectively on day 1 and day 4 post-
transfection. In addition, cells were visualized by phase-contrast microscopy (PC) and nuclei by 
DAPI (4’, 6-diamidino-2-phenylindole) staining. Cells were fixed on day 1 and day 4 post-
transfection and images were taken using a phase contrast microscope.  
To test the efficiency of E6-AP silencing, a Western blot analysis was performed. 
However, in HPV-negative cell lines E6-AP protein levels were not reduced to 
equivalent levels as that observed in HPV-negative cell lines within a similar time 
frame (Figure 15A). However, a relative quantitative RT-PCR analysis revealed that 
E6-AP mRNA levels were reduced to similar extents (approximately two to three fold) 
in HPV-positive cells and HPV-negative cells by the siRNA used (compare Figure 9C 
and Figure 15C). This apparent paradox (similar effect on RNA levels but different 
effect on protein levels) is possibly explained by the notion that E6-AP has a rather 
long half-life in HPV-negative cells but is targeted for proteasome-mediated 
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degradation by the E6 oncoprotein in HPV-positive cells (Kao et al., 2000). Thus, it is 
expected that transient siRNA treatment affects E6-AP levels in HPV-positive cells 
more significantly than in HPV-negative cells.  
 
 
 
Figure 15: Down-regulation of E6-AP and Hdm2 in MCF7 cells. A. Western blot 
analysis of E6-AP down-regulation. MCF-7 cell line was transfected with either si-control or 
si-E6-AP1 siRNA on a 6 well plate. Total protein lysates was prepared 48 hrs post-transfection 
and analyzed by western blot analysis using anti-E6-AP monoclonal antibody. C. Relative 
quantitative reverse transcription PCR analysis. Silencing of E6-AP mRNA was determined at 
48 hrs post-transfection by isolating total mRNA from siRNA treated cells. Relative 
quantitative reverse transcription PCR analysis was performed using E6-AP specific primers 
which results in a 750bp amplification product. As an internal standard, 18s rRNA was 
amplified (488 bp product).  
4.3.2 Stable knockdown of E6-AP expression in a H1299, a HPV-
negative cell using shRNA expression vectors 
Transient silencing of E6-AP expression using synthetic siRNA had suggested that 
down-regulation of E6-AP does not have a growth suppressive in HPV-negative cells. 
However, E6-AP protein levels were not completely abrogated and thus it remained 
unclear if E6-AP is required for cell viability in HPV-negative cell lines. Therefore, 
shRNA expression vector targeting E6-AP (pRS-sh-E6-AP1) was transfected into 
H1299 cells and transfected cells were selected out with puromycin. Cells exhibiting 
puromycin resistance was used to generate single clonal cell lines stably expressing E6-
AP shRNA (Material and Methods, 3.2.10). Cell lysates were prepared from these 
clonal cell lines and endogenous E6-AP levels were analyzed by Western blot analysis. 
While some of the single cell clones generated did show decrease in E6-AP levels 
(knockdown ranging from 30-40%), the efficiency of knockdown was insufficient to 
rule out the possibility that the available E6-AP is sufficient for viability (data not 
shown).  
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Further to this, since sh-E6-AP2 sequence was more efficient than sh-E6-AP1 (Figure 
8) attempts were also made to generate stable clones using this sequence. Hence pRS-
sh-E6-AP2 was transfected into HeLa and H1299 (HPV-negative) cell lines and clones 
exhibiting puromycin resistance were picked. In comparison to HeLa cells (HPV-
positive cells) wherein down-regulation of E6-AP has a strong growth suppressive 
effect (see also Figure 13) single cell clones of H1299 were obtained exhibiting 
significant decrease in E6-AP levels as determined by western blot analysis (Figure 
16). This would suggest that in comparison to HPV-positive cell lines, HPV-negative 
cell lines require lower threshold levels of E6-AP for viability (see also Discussion). 
 
 
 
Figure 16: Stable knockdown of E6-AP expression in a H1299, a HPV-negative 
cell using shRNA expression vectors. H1299 cell line was transfected with either pRS-sh-
control or pRS-sh-E6-AP2. Cells were selected for puromycin resistance and single cell clones 
established. Levels of E6-AP in these single cell clones were determined by western blot 
analysis using E6-AP specific monoclonal antibody. Of the ten clones picked, three of the 
clones (H12-2, H12-6, H12-7) showed significant decrease in E6-AP levels. To compare with 
initial endogenous E6-AP levels, parental H1299 cell lysates (Par) and one of the puromycin 
resistant clones established from transfection for pRS-control (Luc) is loaded. 
Taken together the results described above corroborate previous data indicating that 
E6-AP is required for both p53 degradation (Beer-Romero et al., 1997; Traidej et al., 
2000; Hengstermann et al., 2001; zur Hausen, 2002; Kim et al., 2003; Kelley et al., 
2005) and the viability of HPV-positive cells lines. However, since E6-AP is implicated 
in E6-mediated degradation of proteins other than p53 (e.g., E6TP1 and hscrib) it 
remains unclear if the apoptosis enhancing effect is directly linked to the ability of E6-
AP to target p53 for degradation or whether other yet uncharacterized functions of E6-
AP are also involved. One possible way to address this issue is to generate HPV-
positive cells, in which expression of endogenous wild-type p53 is abrogated. The 
rationale for such an approach is the assumption that if the anti-growth-suppressive 
activity of E6-AP is functionally linked to its ability to degrade p53, p53-null HPV-
positive cells should be less sensitive towards siRNA-mediated down-regulation of E6-
AP expression. 
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4.4 Stable suppression of p53 
4.4.1 Validation of p53 knockdown construct 
In order to bring about stable silencing of p53 expression, DNA-based shRNA 
expression vector (pSUPER) designed against p53 (sh-p53) was employed 
(Brummelkamp et al., 2002b). The predicted transcript of sh-p53 is shown in Figure 
17A. To test the efficacy of this vector, initial proof of principle experiments were 
performed. 
 
Figure 17: Validation of shRNA vector targeting p53. A. Predicted transcript of sh-p53 
(Brummelkamp et al., 2002b). B. Western blot analysis of p53 down-regulation. 25ng of a p53 
expression vector was co-transfected with increasing amounts of sh-p53 into H1299 cells (p53 
null, lung carcinoma). The total DNA amount was retained the same in each transfection by 
equalizing with empty vector. Levels of p53 were determined 24 hrs post-transfection by 
western blot analysis. C. Immunofluorescence analysis. p53 expression vector was co-
transfected with a shRNA vector targeting either renilla luciferase (sh-control) or sh-p53 into 
H1299 cells and levels of p53 expression were determined by immunofluorescence. Cells were 
simultaneously stained with DAPI for nuclei staining.  
A wild-type p53 expressing construct was co-transfected with increasing amounts of 
sh-p53 into H1299 cells, a p53 null cell line. To normalize for total amounts of DNA 
transfected, a construct targeting renilla luciferase (sh-control) was used. Protein 
extracts were prepared 24 hrs post-transfection and p53 levels were determined by 
Results  
 56
western blot analysis using a p53 specific antibody (Figure 17B). p53 protein levels 
were significantly reduced with increasing amount of sh-p53 vector transfected 
indicating an efficient knockdown. These results were also substantiated by 
immunofluorescence analysis (Figure 17C). 
4.4.2 Generation of stable p53 knockdown cell lines  
To generate stable p53 knockdown cell lines, HPV-positive (HeLa and SiHa) were co-
transfected with sh-p53 and a vector containing a neomycin resistance marker 
(Materials and Methods, 3.2.10.2). The HPV-negative cell line RKO, which expresses 
high levels of wild type p53, was also transfected as a control to test the efficiency of 
the vector system to bring about stable suppression. Transfected cells were selected 
with G418 and single cell clones stably expressing the neomycin resistance gene were 
established. Single cell clones obtained were then tested for reduction in p53 levels by 
western blot analysis. While some of the neomycin resistant clones (marked with 
asterisks) showed significantly decreased levels of p53 (Figure 18A-C), others did not. 
This could be due to preferential integration of the resistance vector or due to 
inactivation of the RNAi construct in these clones. 
 
 
Figure 18: Generation of p53 knockdown HPV-positive and HPV-negative cell 
lines. HPV-negative cell lines (RKO) and HPV-positive cell lines (HeLa and SiHa) were co-
transfected with sh-p53 vector and a vector expressing the neomycin resistance gene. Cells 
were selected out for neomycin resistance and single cell clones established. Levels of p53 in 
these single cell clones were determined by western blot analysis using p53 specific antibody. 
(A to C) are representative western blots of single cell clones. Asterisk marks indicate single 
cell clones showing stable knockdown of p53. 
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4.4.3 Stress induced activation of p53 in HeLa and SiHa stable 
clones down-regulated by pSUPER –p53 
Upregulation of p53 levels in response to various stimuli is, at least in part, achieved by 
significantly attenuated degradation (Balint and Vousden, 2001; Michael and Oren, 
2003). Experiments using anti-tumour drugs such as Actinomycin D (AD) have shown 
that it is a potent activator of p53 and leads to accumulation of p53 levels (Hietanen et 
al., 2000). Similarly inhibition of proteasomal degradation using proteasomal inhibitors 
such as MG132 leads to stabilization of p53 levels. Although western blot analysis 
revealed that p53 was reduced to non-detectable levels in the HeLa and SiHa stable 
clones (Figure 18B and C), it was necessary to determine if these clones were indeed 
null with respect to p53 protein levels. 
 
 
 
Figure 19: Activation with ActD in down-regulated p53 HeLa clones. A. Parental 
HeLa cells (Par.) and the clones HA1 and HC2 were treated with for 24hrs with 2.5nM and 
5nM Actinomycin D (ActD) as indicated or, as a control, with dimethyl sulfoxide (-). Levels of 
p53 were determined by Western blot analysis. B. Parental HeLa cells (Par.) and the single cell 
clones HA1 and HC2 were treated for 24hrs with 5nM Actinomycin D (ActD) or as a control, 
with dimethyl sulfoxide (-). Levels of p53 were determined by immunofluorescence (p53). In 
addition cells were visualized by phase contrast microscopy (PC) and nuclei by use of DAPI 
(DAPI). 
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4.4.3.1  HeLa  
To obtain further evidence that p53 expression was indeed abrogated in these stable 
clones, p53 levels were determined upon treatment with Actinomycin D. For this, 
parental HeLa cells and the clones exhibiting down-regulated p53 levels were treated 
with 2.5nm and 5nm AD. Protein lysates were prepared 24 hrs after treatment and p53 
levels determined by western blot analysis. Whereas AD treated parental HeLa cells 
exhibited significant p53 accumulation, p53 accumulation was not observed in two of 
the HeLa clones, HA1 and HC2 (Figure 19A), indicating that they were indeed null p53 
expression. To substantiate this observation, wild type HeLa cells and the clones HA1 
and HC2 were treated with 5 nm of Actinomycin D and p53 levels determined by 
immunofluorescence analysis (Figure 19B). As in the previous experiment, no 
detectable levels of p53 stabilization was observed in HA1 and HC2 clones confirming 
that the clones were indeed p53 null. Furthermore, treatment with the proteasomal 
inhibitor MG132 also gave the same result (Figure 20). 
 
Figure 20: Treatment with of HeLa cell lines with MG132. Parental HeLa cells (Par.) 
and the clones HA1 and HC2 were treated with 10µM MG132 for 4 hrs as indicated or, as a 
control, with dimethyl sulfoxide (-). Levels of p53 were determined by Western blot analysis 
using a p53 monoclonal antibody. As a control for loading and MG132 effect, the blot was also 
probed with anti-Dlg mouse monoclonal antibody 2D11. 
As indicated above, the viral E6 and E7 oncoprotein is continuously expressed in HPV-
positive cancer cells lines. To confirm that the stable clones obtained, were indeed 
derived from HeLa cells, levels of E7 protein in the parental HeLa cells were compared 
to the two p53 null clones, HA1 and HC2 by western blot analysis. As a negative 
control, lysates from C33-A, an HPV-negative cervical carcinoma cell line was loaded. 
As shown in Figure 21 expression of the E7 oncoprotein in the p53-null HeLa cell lines 
were not affected demonstrating that they were indeed derived from HeLa cells. Taken 
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together these results indicate that expression of p53 is completely, or almost 
completely, abrogated in the HeLa clones HA1 and HC2. 
 
 
Figure 21: Comparison of E7 levels in parental HeLa and clones HA1 and HC2. 
Levels of the HPV-18 E7 protein in parental HeLa cells (Par.) and the clones HA1 and HC2 
were determined with a polyclonal anti-E7 antibody by western blot analysis. Extracts prepared 
from HPV-negative C33-A cells (C33) served as a negative control 
4.4.3.2 SiHa  
Of all the SiHa clones which showed significant down-regulation of p53 two clones 
showing maximum down-regulation (clones S-10 and S-11) were taken to check 
whether p53 expression was indeed abrogated. Although p53 levels were significantly 
lower in these clones than in parental SiHa cells, treatment with Actinomycin D or 
MG132 led to accumulation of p53 suggesting that p53 was still expressed in these 
clones though at low levels (Figure 22). 
 
 
 
Figure 22: Treatment with Act D and MG132 in SiHa clones. A. Parental SiHa cells 
(Par.) and the clones Cl-10 and Cl-11 were treated with for 24hrs with 2.5nM and 5nM 
Actinomycin D (ActD) as indicated or, as a control, with dimethyl sulfoxide (-). Levels of p53 
were determined by Western blot analysis. B. Parental SiHa cells (Par.) and the clones Cl-10 
and Cl-11 were treated with for 4hrs with 10µM MG132 as indicated or, as a control, with 
dimethyl sulfoxide (-). Levels of p53 were determined by Western blot analysis. 
As an alternative strategy, to obtain SiHa cell lines in which p53 expression was 
abrogated, a retroviral vector targeting p53 (pRS.sh-p53) was transfected into SiHa 
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cells and stable clones were selected using puromycin. Although in total more than 100 
single cell clones were tested for p53 knockdown, none of the stable cell lines showed 
complete abrogation of p53 expression (data not shown and see also Discussion 5.4) 
4.5 Down-regulation of E6-AP in p53 null clones HA1 and HC2 
To determine whether the ability of E6-AP to target p53 for degradation in the presence 
of E6 is essential for the viability of HPV-positive cancer cells or whether other yet 
uncharacterized functions of E6-AP are involved, the p53–null clones HA1 and HC2 
were transfected with E6-AP specific siRNAs and the effects of E6-AP down-
regulation on p53 and on cell viability determined (Figure 23). As expected, p53 was 
not detectable in the p53-null cells even 4 days after transfection. Remarkably, down-
regulation of E6-AP with E6-AP siRNA1 and E6-AP siRNA2 did not interfere with the 
viability of p53-null HeLa cells. Furthermore, no signs of apoptosis in the p53- null 
cells were observed under conditions in which apoptosis in parental HeLa cells was 
significantly induced. Both the transfection efficiencies (Figure 24A and B) and the 
efficiencies of siRNA mediated down-regulation of E6-AP levels (Figure 24B) were 
similar for p53-null cells and parental HeLa cells. 
 
Figure 23: Down-regulation of E6-AP expression does not interfere with the 
growth of p53-null HeLa cells. E6-AP specific synthetic siRNA were transfected into HeLa 
cells (Par.) and the p53-null clones HA1 and HC2. Levels of p53 and induction of apoptosis 
were determined by immunofluorescence and TUNEL assay (TdT-mediated dUTP-biotin nick 
end labeling) respectively on day 1 (24hrs) and day 4 (96hrs) post-transfection. In addition, 
cells were visualized by phase-contrast microscopy (PC) and nuclei by DAPI (4’, 6’-diamidino-
2-phenylindole) staining.  
Results  
 61
 
Figure 24: Transfection efficiency and knockdown. A. To compare transfection 
efficiencies of parental HeLa cells (Par.) and the HeLa derived p53-null clones HA1 and HC2 
were incubated with FITC-dextran in the presence (FITC+oligof.) or absence (FITC-oligof.) of 
Oligofectamine (Invitrogen) as indicated. In addition, nuclei were visualized by use of DAPI. 
B. E6-AP levels were determined by Western blot analysis using a mouse monoclonal 
antibody. 
4.6  RNAi-rescue assays 
The data presented so far indicate that under cell culture conditions the growth 
suppressive phenotype of E6-AP down-regulation in HPV-positive cell lines, is 
dependent on p53. Initial reports of gene silencing using RNAi technology suggested it 
to be highly specific. However, recent reports do indicate “off-target” gene regulation 
by RNAi in some cases (Jackson et al., 2003; Scacheri et al., 2004; Snove and Holen, 
2004). In addition to using two different siRNA/shRNAs targeting sequences against 
E6-AP to further substantiate the above result an attempt was made to rescue the 
phenotype. Such a rescue approach could also be exploited to test the ability of 
different mutant forms of E6-AP to rescue the phenotype, thus performing “quasi 
genetics” within cells, thereby correlating the biochemical activities of a particular 
protein such as E6-AP to its biological role within a cell.  
4.6.1 Validation of rescue constructs 
One possible approach to rescue the phenotype of RNAi-mediated down-regulation of a 
given protein is by overexpressing an “RNAi–resistant” expression construct of the 
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target gene. RNAi depends upon perfect complementarity between siRNA/shRNA and 
the RNAi targeting sequence (within the mRNA). Thus an “RNAi-resistant” rescue 
construct can be created by introducing silent point mutations at the siRNA/shRNA 
target site while still maintaining the same amino acid sequence. In contrast, an 
overexpression construct with perfect complementarity will be “RNAi-susceptible”. 
To generate an RNAi-resistant rescue constructs of E6-AP, E6-AP expression 
constructs with two silent point mutations (Figure 25A) at the si/shRNA target site 
corresponding to either si/sh-E6-AP1 (E6-AP.mut1) or si/sh-E6-AP2 (E6-AP.mut2) 
were generated in the mammalian expression vector, pEF1/V5-His in which 
overexpression is driven by a cellular house keeping promoter, the human elongation 
factor 1α (hEF-1α). In order to differentiate between the endogenous and ectopically 
expressed E6-AP, an N-terminal haemagglutinin tag (HA) was incorporated into the 
construct. The logic behind introducing two silent mutations was based on the finding 
that even a single mismatch at the siRNA-targeting region obliterates silencing 
(Elbashir et al., 2001). To confirm whether these constructs were indeed resistant to 
RNAi against E6-AP, the ability of sh-E6-AP1 and sh-E6-AP2 to downregulate E6-AP 
expression from E6-AP.mut1 or E6-AP.mut2 was tested by transient co-transfection 
assay (Material and methods, 3.2.3). The ability of sh-E6-AP1 or sh-E6-AP2 to 
downregulate E6-AP expression from an RNAi susceptible vector (wt-E6-AP) 
construct was also compared as a control. As shown in Figure 25B, as expected, ectopic 
E6-AP expression from the wt-E6-AP was down-regulated upon co-transfection with 
sh-E6-AP2 and not with the sh-control. In comparison, ectopic E6-AP expression from 
E6-AP.mut2 was not downregulated indicating that this construct was resistant to 
RNAi. Hence this construct was used in further rescue experiments. In comparison, co-
transfection of sh-E6-AP1 with E6-AP.mut1 indicated that E6-AP expression from this 
vector was silenced nearly as efficiently as an RNAi susceptible E6-AP vector and 
hence could not be used for a rescue approach (data not shown). As compared to the 
earlier report of Elbashir et al, wherein RNAi was reported to be highly specific, a 
recent report has indicated that in some cases, a variable degree of gene silencing can 
still occur  in spite of nucleotide mismatches, depending on the position of the 
mismatch (Pusch et al., 2003). This could be a reason for silencing of expression even 
from E6-AP.mut1 vector. 
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Figure 25: Validation of rescue constructs. A. siRNA/shRNA target sequence in E6-AP 
and corresponding silent point mutations (indicated in bold and underlined) in the rescue 
constructs E6-AP.mut1 and E6-AP.mut2. B. pRetroSUPER shRNA construct targeting E6-AP 
(sh-E6-AP2) or renilla luciferase (sh-control) were co-transfected individually with either a HA 
tagged wt-E6-AP (RNAi susceptible) or E6-AP.mut2 (RNAi resistant) expression constructs 
into H1299 cells. 24hrs post-transfection exogenously expressed E6-AP levels were determined 
by western blot analysis using anti-HA antibody. C. sh-control (targeting renilla luciferase) or 
sh-E6-AP1 (targeting E6-AP) was co-transfected individually with HA tagged E6-AP.∆N30 
expression construct or HA-tagged wt-E6-AP construct into H1299 cells. 24hrs post-
transfection exogenously expressed E6-AP levels were determined by western blot analysis 
using anti-HA antibody. * indicates the running position of ectopically expressed E6-AP. 
Since the initial attempt to generate an RNAi resistant construct against sh-E6-AP1 was 
unsuccessful, as an alternative approach, a construct of E6-AP having an N-terminal 
deletion of 30 amino-acids (and thus lacking the sh-E6-AP1 target site) was generated. 
(E6-AP.∆N30). E6-AP lacking the N-terminal 30 amino acids has been shown to be 
sufficient for E6/E6-AP mediated degradation of p53 (Huibregtse et al., 1993). To 
confirm whether this construct is resistant to RNAi, the ability of sh-E6-AP1 to silence 
expression of E6-AP from wt-E6-AP or E6-AP.∆N30 construct were compared by 
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transient co-transfection. As shown in Figure 25A, while expression from wt-E6-AP 
was significantly down-regulated, the expression from E6-AP.∆N30 construct was 
resistant to silencing and was used for further rescue experiments. 
4.6.2 Overexpression of E6-AP in HPV-positive cells and HPV-
negative cells 
In order to rescue the growth suppressive phenotype of E6-AP in HPV-positive cells, 
an experimental design as outlined in Figure 26A (strategy 1) was initially tested. This 
strategy involved co-transfection of a shRNA expression vector (sh-E6-AP1 or 2) and 
either the overexpression construct of E6-AP which is RNAi susceptible (wt-E6-AP) or 
a corresponding E6-AP construct which is resistant to RNAi (E6-AP.∆N30 or E6-
AP.mut2). By using colony formation assays (as shown in Figure 13) to compare the 
number of colonies obtained, a rescue of the phenotype could be determined.  
Experiments conducted in HeLa cells using this strategy however did not show any 
significant rescue of this phenotype (data not shown). To rule out the possibility that 
the inability to rescue the growth suppressive phenotype was due to the experimental 
strategy involved, an alternative strategy as depicted in Figure 26B (Strategy 2), was 
attempted. This strategy involved initially generating stable cell lines overexpressing 
E6-AP either from the RNAi susceptible or RNAi resistant expression constructs and 
comparing their ability to rescue the growth suppressive phenotype upon down-
regulation of E6-AP by using synthetic siRNA or shRNA vectors. 
Hence the E6-AP expressing RNAi resistant or RNAi susceptible constructs were 
individually transfected into HeLa cells and stable pooled clones exhibiting neomycin 
resistance were established. However, in the course of these experiments it was 
unexpectedly observed that that stable ectopic overexpression of E6-AP led to decrease 
in cell viability as compared to cells transfected with an empty vector (data not shown). 
Of the clonal population that were neomycin resistant, protein lysates of these pooled 
clones were prepared and analyzed by IP-Western blot analysis using an anti-HA 
antibody to detect specifically the overexpressed E6-AP. As shown in Figure 27 B 
(lane-1), it was not possible to stably overexpress E6-AP either from the RNAi 
susceptible construct or the RNAi resistant construct (data not shown). This was in 
spite of the ability to overexpress E6-AP from these constructs in transience (Figure 
27A, lane 2 and data not shown). This inability to overexpress E6-AP was also found to 
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be the case in SiHa and CaSki cell lines which are positive for HPV16 and HPV18 
respectively. Similar experiments to stably overexpress E6-AP in HPV-negative cell 
lines, namely H1299, MCF-7 and RKO exhibited stable overexpression of E6-AP 
(Figure 27C, lane 2 and data not shown). This would suggest that E6-AP 
overexpression has a negative effect on cell growth and thus results in selective 
outgrowth of clones that do not overexpress E6-AP. 
 
 
 
Figure 26: Experimental strategy for RNAi rescue. In strategy 1, the RNAi silencing 
construct and the overexpression construct are simultaneously transfected and colonies 
exhibiting resistance for both the constructs are selected. In case of cells transfected with the 
RNAi susceptible overexpression construct the knockdown of both endogenous and ectopically 
expressed E6-AP leads to a growth suppressive phenotype in HPV-positive cell lines. However 
in the case of cells transfected with the RNAi resistant construct, rescue of the growth 
suppressive phenotype is expected. In strategy 2, stable cell lines expressing the RNAi 
susceptible/resistant constructs are first generated and then subjected to RNAi to determine 
rescue of the phenotype. 
To determine whether the apparent inability to overexpress E6-AP was dependent on its 
ability to interact with E6, a deletion construct lacking the E6 binding site (E6-AP.∆E6) 
with an N-terminal HA tag was generated. The expression of this construct was tested 
in a transient transfection experiment in HeLa cells and was found to be expressed at 
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levels equivalent to wild type E6-AP under these experimental conditions (Figure 27A, 
lane 3). To determine whether E6-AP.∆E6 can be stably overexpressed in HeLa cells, 
stable pool of clones transfected with this vector exhibiting neomycin resistance were 
established. Cell lysates of these clonal populations were prepared and analyzed by IP-
western blot analysis. Indeed, it was possible to overexpress the E6-AP mutant lacking 
the E6 binding site (Figure 27, lane 2). Taken together the above experiments indicate 
that the inability to detectably overexpress E6-AP depends on the E6 binding region. 
Together with the inability to rescue the growth suppressive phenotype by strategy 1, 
these data suggested that overexpressed E6-AP is toxic to HPV-positive cells lines.
 
 
 
Figure 27 Overexpression of E6-AP in HPV-positive HeLa cell line and HPV-
negative H1299 cell line. A. Transient expression of HA tagged wild type E6-AP (WT), E6-
AP lacking the 18 amino acid E6 binding region (∆E6). HeLa cells were transfected with the 
indicated constructs and expression levels of the various constructs were determined 24 hr post-
transfection by western blot analysis and detection with an anti-HA antibody. NT:non-
transfected cells. B. Stable overexpression of E6-AP. HeLa cells were transfected with vectors 
encoding either WT or ∆E6 form of E6-AP. Transfected cells were selected for with G418 for 
two weeks Overexpressed E6-AP levels were determined in pooled clones by western blotting 
with an anti-HA antibody. C. H1299 cells were transfected with vector encoding wild type E6-
AP (wt) and selected for 2 weeks with G418. Overexpressed E6-AP levels were determined as 
in B.  
4.6.3  Transient rescue assay 
Since a rescue of the growth suppressive phenotype of E6-AP in HeLa cells was not 
possible by colony formation assays, alternatively, to establish a rescue approach 
transient assays were tested wherein p53 accumulation was monitored as “rescue 
readout”. To this end, pRS-sh-E6-AP2 construct was cotransfected into HeLa cells with 
the expression vector, wt-E6-AP or E6-AP.mut2. An RNAi resistant construct of E6-
AP lacking the E6 binding site (E6-AP ∆E6.mut2) was also similarly transfected in 
parallel. Likewise, co-transfection of the individual E6-AP vectors (namely, wt-E6-AP, 
E6-AP.mut2 and E6-AP ∆E6.mut2) with pRS-control served as negative controls. 
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Transfected cells were selected with puromycin resistance (encoded by the pRS 
construct). Protein lysates of puromycin selected cells were prepared 96 hrs post-
transfection, and a Western blot analysis was performed to detect ectopically expressed 
E6-AP with an anti-HA antibody. Endogenous p53 levels were also detected with an 
anti-p53 antibody. As indicated in Figure 28, silencing of endogenous E6-AP in cells 
by pRS-sh-E6-AP2 led to p53 accumulation (lane 2). While this accumulation was not 
rescued by overexpression of E6-AP from an RNAi-susceptible expression vector due 
to down-regulation of the overexpressed E6-AP (lane-4), ectopically expressed E6-AP 
from the RNAi-resistant construct E6-AP.mut2 rescued p53 accumulation by 
approximately 80% as determined by quantification of the p53 band (lane 4). As 
expected, the RNAi-resistant construct E6-AP∆E6.mut2 did not rescue p53 
accumulation. This indicates that the effect of p53 stabilization is indeed due to the 
down-regulation of E6-AP and not due to an “off target” effect. 
 
Figure 28 Transient rescue of p53 stabilization. E6-AP RNAi construct pRS-sh-E6-AP2 
was co-transfected with either the RNAi-susceptible construct (HA.E6-AP) or the RNAi 
resistant construct (HA.E6-AP.mut). As negative control the pRS-control vector was also co-
transfected with HA.E6-AP or HA.E6-AP.mut2. Cells expressing the RNAi construct were 
selected for by puromycin selection. 72 hours post-transfection cells were lysed and western 
blot analysis was performed. Overexpressed E6-AP was detected using anti-HA antibody, 
while p53 was detected using an anti-p53 DO-1 antibody. 
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4.7 Visualization of subcellular interactions using Bimolecular 
fluorescence complementation assay (BiFC) 
The BiFC assay has been shown to be a suitable technique to visualize protein-protein 
interactions in living cells by reconstitution of the yellow fluorescent protein from two 
fragments attached to two interacting proteins (see Introduction, 1.5). Hence, in order to 
visualize interactions of E6-AP in living cells, an attempt was made to establish the 
BiFC assay.  
To evaluate the BiFC assay, initial proof of principle experiments were performed 
using the bZip domains of Fos and Jun tagged to the YFP fragments (Figure 29A) as 
reported by Hu and coworkers. Therefore, bFosYC and bJunYN expression vectors 
were co-transfected into H1299 cells seeded on coverslips. As a measure of transfection 
efficiency, a vector encoding full length YFP was transfected in parallel. As negative 
controls, bFosYC was co-transfected with the YN vector lacking bJun and likewise 
bJunYN expression vector was co-transfected with the YC vector lacking bFos. 
Although BiFC can be directly visualized in living cells, in this particular experiment 
cells were fixed after 24 hours, nuclei stained with DAPI and visualized by 
fluorescence microscopy (Materials and Methods, 3.2.7.6). While bFosYC or bjunYN 
alone did not give any detectable fluorescence complementation (panel-2, 3), co-
transfection of both the constructs into H1299 cells gave fluorescence which was 
nuclear with preferential localization to the nucleoli (Figure 29B, panel-4). This 
experiment confirmed the utility of BiFC to visualize protein interactions as reported by 
Hu and coworkers. 
A number of potential substrates of E6-AP have been identified to date (see 
Introduction). To establish the BiFC assay to visualize the interactions of E6-AP with 
its potential binding partners within cells, a recently identified interacting partner, 
HERC2 (homologous to E6-AP C-terminus and RCC1), was chosen (Sandra Glockzin, 
Ulrike Kogel and Martin Scheffner, unpublished results). HERC2 was identified in a 
yeast two hybrid screen and the RCC1b domain of HERC2 has been shown to be 
sufficient to interact with E6-AP in vitro and in vivo. Since HERC2 is a large protein of 
528 kDa, and the full length cDNA is unavailable, the RCC1b domain of mu-HERC2 
was selected for studying its interaction with E6-AP. Hence, fusion constructs of E6-
AP with the C-terminal fragment of YFP (E6-AP.YC) and the RCC1b domain (2959-
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3327) of mHERC2 with the N-terminal fragments of YFP (RCC1b.YN155) were 
created (Figure 30A). 
  
Figure 29: Bimolecular fluorescence complementation (BiFC) of bFosYC155 and 
bJunYN155. A. Schematic representation of the bFosYC155 and bJunYN155 constructs (Hu 
et al., 2002). B. BiFC of the bZIP domains of Fos and Jun. The indicated constructs were 
transfected into H1299 cells seeded on coverslips placed in a 24 well plate. 24 hrs later the cells 
were fixed and nuclei stained with DAPI. As a positive control for fluorescence full length YFP 
was also transfected (panel 1). Phase contrast (PC), DAPI, and Fluorescence images (YFP) 
were taken using an Olympus fluorescence microscope. Arrow marks indicate fluorescence 
complementation and localization of the bFos and bjun proteins. 
To determine whether these fusion constructs interact within cells, co-
immunoprecipitation analysis was performed in H1299 cells co-transfected with the 
indicated constructs as shown in Figure 30B. Co-precipitation analysis revealed that it 
was possible to immuno-precipitate out HA-E6-AP.YC by RCC1b.YN (lane-3). This 
was also found to be as efficient as the non-fused fragment of murine HERC2 (2818-
3606) encompassing the RCC1b domain (lane-2). This indicated that the two fusion 
constructs could interact with one another within cells. In order to visualize this 
interaction of E6-AP and the RCC1b domain, the fusion constructs were transfected 
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into H1299 or Cos-7 cells and monitored for fluorescence complementation. Even 
though co-precipitation analysis had indicated that the E6-AP and RCC1B fusion 
proteins interact within cells, no fluorescent complementation was detected (data not 
shown). One possibility for the lack of complementation could be that the two YFP 
fragments as fusion constructs were stearically hindered in fluorophore formation. 
Another possibility could be that the two YFP fragments were too far apart to 
reconstitute the fluorophore. Hence as an alternative strategy, the respective YFP 
fragments were recloned at the N-terminus of E6-AP and RCC1b (Figure 31). The 
expression of these constructs was tested (data not shown) and their ability to form 
fluorescent complexes within cells was evaluated. However, no fluorescence 
complementation was observed even with the new constructs with the YFP fragments 
at the N-terminus. To rule out that it was a cell line specific problem, these experiments 
were also performed in HeLa, and Cos-7 cells with similar outcome. 
 
Figure 30: Generation of BiFC constructs of E6-AP and RCC1b domain of 
HERC2. A. Schematic representation of the cloning strategy used for generation of BiFC 
constructs with C- terminal YFP fragments. B. Co-immunoprecipitation analysis of E6-AP and 
RCC1b BiFC constructs. The indicated constructs were co-transfected into H1299 cells and co-
immunoprecipitated using HA antibody. Asterisks indicate the running position of the heavy 
and light chains of the antibody. ? unknown band. 
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Figure 31: Schematic representation of the cloning strategy used for generation of 
BiFC constructs with N- terminal YFP fragments. Asterisk mark indicates that a similar 
construct was prepared by replacing wild type E6-AP with a C820A inactive mutant. 
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5. Discussion 
Recent studies suggest that many of the known functions of E6 are mediated via 
complex formation with E6-AP (see Introduction, 1.3.3). For example, microarray 
analyses of HPV-positive cancer cell lines in which either E6 or E6-AP expression was 
down-regulated by RNAi indicate that the effects of E6 on the transcription program of 
its host cell are mediated in complex with E6-AP (Kelley et al., 2005). While many 
studies addressed the role of E6-AP in HPV-positive cells, only little is known about its 
physiological function in normal cells. Indeed, even though the genetic disorder 
Angelman syndrome has been linked to the loss of E6-AP E3 ligase activity (Cooper et 
al., 2004), it is still unclear whether deregulated degradation of E6-AP substrate(s) are 
responsible for this disorder and if so the respective substrate(s) are yet to be identified. 
The RNA interference (RNAi) technology provides a powerful tool to study the 
proposed role(s) of individual genes or gene products within cells and can be used in 
mammalian cell culture studies. In the present study, to gain insights into the 
physiological role of E6-AP, RNAi was employed to down-regulate E6-AP expression 
in HPV-positive and HPV-negative tumour cell lines. The consequences of E6-AP 
down-regulation on growth and cell viability were studied. 
5.1 Knockdown of E6-AP in HPV-positive cervical cancer cell lines 
results in growth suppression 
The E6 and E7 oncoproteins are generally the only viral proteins that are continuously 
expressed in HPV-positive cervical cancer cells and are necessary for the maintenance 
of the malignant phenotype of these cells. Indeed, inactivation of E6 by using either 
peptide aptamers or RNAi leads to activation of the p53-dependent apoptotic pathway 
in HPV-positive cancer cells (Butz et al., 2000; Butz et al., 2003). Similarly selective 
silencing of E7 by RNAi has also been reported to lead to apoptotic cell death (Jiang 
and Milner, 2002). The functional dependency of E6 on E6-AP has previously been 
studied by using either antisense or ribozyme mediated gene suppression strategies in 
HPV-positive and HPV-negative cells (Beer-Romero et al., 1997; Kim et al., 2003). 
However, in these experimental setups, no effects on cell growth or apoptosis were 
detected, although the cells were more sensitized to DNA damaging agents. In the 
present study, RNAi mediated down-regulation of E6-AP has further confirmed that 
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E6-AP is essential for efficient p53 degradation in HPV-positive cancer cell lines. In 
addition, E6-AP down-regulation resulted in growth suppression and apoptosis. In 
comparison to the above utilized techniques, the RNAi approach is assumed to be more 
efficient and has the ability to sustain gene silencing for longer periods of time 
(Kennerdell and Carthew, 1998; Elbashir et al., 2001). Hence, less efficient interference 
with E6-AP activity could be the reason for the inability to see the observed phenotype 
in earlier studies. In any case, the results presented here support the notion that E6-AP 
has anti-growth suppressive properties in HPV-positive cancer cells. 
Of the four identified si/shRNAs targeting the E6-AP ORF, two sequences which gave 
the most efficient down-regulation of E6-AP were further used for E6-AP 
characterization. Of the two sequences, the E6-AP2 target sequence either as synthetic 
siRNA or short hairpin RNA was better than the E6-AP1 target sequence at down-
regulating E6-AP, both at the protein and mRNA level (Figure 9B and C). Colony 
formation assays using RNAi vectors in HeLa and SiHa cells yielded reduced colony 
numbers with sh-E6-AP1 and sh-E6-AP2 which correlated with the efficiency of 
knockdown (Figure 13). However, although the knockdown efficiency of synthetic si-
E6-AP2 was better than that of si-E6-AP1 on both the protein and mRNA level, the 
efficiency of si-E6AP1 at inducing apoptosis and growth suppression was better in 
HeLa cells (Figure 11). One possible explanation for this effect could be that in some 
cases, synthetic siRNA can lead to ‘off-target’ effects by the recruitment of the sense 
strand into RISC (Nykanen et al., 2001; Khvorova et al., 2003). While this possibility 
cannot be ruled out with the present resources, if this would be the case, then these “off 
target effects” could be minimized in future experiments by utilizing synthetic siRNA 
which have been modified at the 5’ end of the antisense strand of the synthesized 
siRNA with proprietary chemical modifications which are supposed to minimize “off-
target” effects (for instance “ON-TARGET” siRNA from Dharmacon or “Stealth 
siRNA” from Invitrogen). Despite a difference in killing efficiency, the data clearly 
show that down-regulation of E6-AP leads to growth suppression in HPV-positive cell 
lines. A likely mechanism underlying the observed phenotype is illustrated in Figure 
32. 
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Figure 32: Model for the observed phenotype of HPV-positive cervical cancer cell 
lines upon E6-AP down-regulation. In case of HPV-positive cervical cancer cell lines, the 
E6/E6-AP complex targets p53 and other substrates (where X stand for substrates such as 
E6TP1, Scribble, etc,) for ubiquitination and degradation by the 26S proteasome (A). However, 
upon down-regulation of E6-AP expression stabilization of these substrates leads to growth 
suppression (B). 
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5.2 Transient down-regulation of E6-AP in HPV-negative cell lines 
does not have a growth-suppressive effect as compared to HPV-
positive cell lines 
In HPV-negative cell lines, E6-AP does not appear to be involved in p53 degradation 
(Beer-Romero et al., 1997; Talis et al., 1998; Traidej et al., 2000). Although a few 
potential E6-independent substrates of E6-AP have been identified (see Introduction, 
1.3.5) the physiological significance of these interactions is unclear. Moreover, it is 
likely that other interacting proteins of E6-AP are yet to be identified. Since it still 
seems possible that deregulated degradation of one or more substrates of E6-AP could 
result in a growth suppressive phenotype also in HPV-negative cells (i.e the growth 
suppressive phenotype of E6-AP down-regulation does not depend on its ability to 
interact with E6), this was tested by down-regulating E6-AP by RNAi.  
Transient down-regulation of E6-AP using synthetic siRNA in various HPV-negative 
cell lines (i.e. MCF-7, RKO, and U2OS) had no significant effect on p53 stabilization 
which correlated with the results of earlier publications (Beer-Romero et al., 1997; 
Talis et al., 1998). Furthermore, no significant effect on viability was observed as 
compared to HPV-positive cell lines. Although this indicates that transient down-
regulation of E6-AP does not have a growth-suppressive effect in HPV-negative cell 
lines, in this experimental set up it was observed that E6-AP protein levels were not 
down-regulated to similar extents as compared to HPV-positive cell lines (Figure 9B 
and Figure 15A). This was in spite of similar knockdown efficiencies at the mRNA 
level (Figure 9B and Figure 15C, and data not shown). This apparent paradox can 
possibly be explained by differences in E6-AP protein stability. In the case of HPV-
positive cells, E6-AP has been reported to act as a substrate for E6 and hence has a 
shorter half-life than in HPV-negative cells (Kao et al., 2000).  
Transfection of synthetic siRNA is known to bring about transient but not stable 
knockdown of the mRNA due to the fact that siRNA molecules are not amplified in 
mammalian cells as compared to other eukaryotes (e.g. fungi, plants and worms) 
(Zamore, 2002). Thus, the gene silencing is transient since the introduced siRNA gets 
diluted out at each cell division and also probably due to degradation by cellular 
enzymes. Therefore, using synthetic siRNA it was not possible to determine if 
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constitutive down-regulation of E6-AP expression gives a phenotype in HPV-negative 
cell lines. One approach tested to overcome this limitation was to transfect higher 
concentrations of synthetic siRNA. Transfection of higher concentration (ranging from 
100nM to 500nM) of siRNA resulted in more efficient down-regulation of E6-AP 
protein levels and also had effects on viability in comparison to cells transfected with 
similar amounts of control siRNA directed against Renilla luciferase (data not shown). 
This growth suppressive effect was found to be more pronounced with si-E6-AP1 than 
si-E6-AP2 and was also observed in H1299 (a p53 null cell line), indicating that the 
effect was p53-independent. While these data would suggest that E6-AP has anti-
growth suppressive effects in HPV-negative cell lines, it should be noted that RNAi has 
recently been reported to have increased off-target effects at higher siRNA 
concentrations (Persengiev et al., 2004). 
Taken together, the experiments with synthetic siRNA indicate that HPV-negative cell 
lines are more resistant to transient E6-AP down-regulation than HPV-positive cell 
lines. 
5.3 Stable knockdown of E6-AP in HPV-negative cell lines 
In the case of mouse models with maternal deficiency of E6-AP, phenotypic 
abnormalities similar to Angelman Syndrome patients have been observed (Jiang et al., 
1998). Furthermore, while mice with homozygous deletions of E6-AP are viable, the 
postnatal viability is reduced which is more pronounced when bred within the same 
genetic background. To determine whether E6-AP is required for the viability of HPV-
negative cell lines under cell culture conditions, attempts were made to generate E6-AP 
null H1299 (HPV-negative) cell lines. Initial attempts with pooled population of cells 
exhibiting E6-AP down-regulation were found to “loose” the knockdown phenotype 
over several population doublings in spite of maintaining the cells under selection 
pressure. While this may be due to partial integration or inactivation of the silencing 
construct, there could also be the possibility that down-regulation of E6-AP below a 
certain threshold level gives these cells a growth disadvantage as compared to cells 
expressing physiological levels of E6-AP. Over a number of population doublings, such 
a scenario would lead to selective out-growth of cells having above threshold levels of 
E6-AP. Hence, to overcome this potential hurdle, it was attempted to establish clonal 
cell lines of H1299 in which E6-AP expression is abrogated. In contrast to HPV-
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positive cell lines, it was possible to obtain clonal HPV-negative cell lines in which E6-
AP was stably down-regulated by RNAi (Figure 16). This would indicate that under the 
given conditions, HPV-negative cells are less sensitive to E6-AP down-regulation than 
HPV-positive cells. Furthermore, preliminary experiments at establishing clonal cell 
lines of MCF-7 cells in which E6-AP expression is stably down-regulated by RNAi 
indicate that it is possible (data not shown). This data would suggest that the ability to 
obtain clones in which E6-AP is significantly down-regulated does not depend on the 
p53 status in the case of HPV-negative cell lines (since MCF-7 cell lines expresses wild 
type p53 in comparison to H1299 which are p53 null). However, the inability to obtain 
clonal cell lines in which E6-AP is completely abrogated supports the hypothesis that 
certain threshold levels of E6-AP is essential for normal cell viability (Figure 18 and 
data not shown). However, further characterization would be necessary to determine 
whether the inability to establish E6-AP “null” cells is due to the inefficiency of the 
RNAi construct or whether complete knockdown of E6-AP is toxic to cells. In this 
context it should be noted that it is possible to establish growth of E6-AP null mouse 
embryonic fibroblasts in culture. However in this case, it cannot be excluded that such 
cells could have “learnt” to adapt to the lack of E6-AP. Alternatively, the essentiality of 
E6-AP expression could be cell type specific. 
5.4 Growth-suppression induced by down-regulation of E6-AP in 
the HPV-positive cancer cell line HeLa, depends on p53 
expression 
While E6-AP down-regulation led to a growth suppressive phenotype in HPV-positive 
cells with concomitant increase in p53 stability, these observations do not answer the 
question as to whether p53 is the main or only target of the E6/E6-AP complex that is 
relevant for growth suppression or whether other E6/E6-AP substrates (e.g. E6TP1, 
Scribble, MCM7 and NFX1-91) also play a role in the observed phenotype. It should 
also be noted that, while an earlier report indicated that the PDZ domain containing 
protein, hDlg (the human homologue of Drosophila disc large protein) was targeted for 
degradation by E6 in an E6-AP independent manner (Mantovani et al., 2001), recent 
evidence indicates that hDlg is also degraded via E6-AP mediated ubiquitination (Petric 
Kuballa and Martin Scheffner, S. Beaudenon and J. Huibregtse, unpublished data). 
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To answer the question whether the anti-growth-suppressive property of E6-AP was 
dependent on its ability to degrade p53, HeLa cell lines in which p53 expression was 
abrogated by RNAi were generated (Figure 18). Down-regulation of E6-AP in these 
cell lines indicated that indeed the anti-growth suppressive properties of E6-AP depend 
on p53 degradation. Likewise, the anti-apoptotic activity of E6 was also found to 
depend on p53 in these cell lines (Arnd Hengstermann and Petric Kuballa, personal 
communication). From these data, a model is proposed for the cell survival pathway in 
p53 null HeLa cells in Figure 33. 
Although the data presented clearly indicate that, under cell culture conditions, p53 
represents the main target for the anti-growth suppressive activities of E6-AP, it cannot 
be excluded that E6-AP has additional p53-independent anti-apoptotic functions in 
HPV-positive cells. As shown in Figure 24A, E6-AP levels were significantly but not 
completely down-regulated upon transfection of siRNA directed against E6-AP in the 
p53-null HeLa clones (see below). Thus, if p53-independent properties of E6-AP are 
required for the growth of HeLa cells, it can be postulated that the threshold level of 
E6-AP required to perform these hypothetical p53-independent functions is lower than 
the one required for E6-AP mediated degradation of p53. Preliminary attempts to 
obtain single cell clones of p53 null HeLa clones in which E6-AP expression is 
completely abrogated suggests that this is not possible. As in the case of HPV-negative 
cells, certain threshold levels may also be required for the E6- independent functions of 
E6-AP for long term cell survival. Furthermore, in the case of HPV-positive cells other 
functions of E6-AP (in association with E6) have been associated with maintenance of 
the malignant phenotype, for example, increased telomerase activity (Munger et al., 
2004). Thus, it is possible that stable down-regulation of E6-AP over a number of 
population doubling times leads to a secondary growth suppressive effect (other than 
due to p53 stabilization) due to telomere shortening. 
In contrast to HeLa cells, it was not possible to generate p53 null SiHa clones. 
Furthermore, the number of clones with significant down-regulation of p53 was low in 
SiHa cells. Of more than 80 clones picked, only 5 of the clones showed close to 
complete abrogation of p53 levels. However, in these clones p53 levels significantly 
increased upon treatment with Actinomycin D or MG132 (Figure 22B and data not 
shown). To exclude the possibility that the RNAi construct per se was not efficient 
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enough to bring about complete knockdown in SiHa cells, transient transfection assays 
were performed in SiHa cells, and the efficiency of p53 knockdown was determined. 
Similar knockdown efficiencies as compared to HeLa cells were observed (data not 
shown). One reason for the inability to generate p53 null SiHa cell lines could be that a 
certain threshold amount of p53 is required for proliferation or viability of SiHa cells. 
In this regard, it is interesting to note that p53 is still functional in HPV-positive 
cervical cancer cell lines and does possess transactivating activity (Butz et al., 1995; 
Butz et al., 1999; Hietanen et al., 2000). Therefore, it could be possible that minimal 
activities of p53 may be required for viability or proliferation. In addition, wild-type 
p53 is assumed to play an important role in ensuring the integrity of the genome, and 
thus, its presence may ensure a degree of genomic stability. Another, but not mutually 
exclusive possibility could be that p53 has been suggested to exert anti-apoptotic 
effects under certain conditions (reviewed in Oren, 2003). and, thus, cells lacking 
functional p53 could be more vulnerable to apoptosis. However, additional experiments 
will be required to address these possibilities. 
 
Figure 33: Model of cell survival pathway in p53 null HeLa cells. Knockdown of E6-
AP in p53 null HeLa cells although leads to stabilization of other substrates of E6-AP, does not 
lead to growth suppression. 
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5.5 RNAi–rescue assays 
To substantiate the results obtained by RNAi, an attempt was made to rescue the 
growth suppressive phenotype of E6-AP down-regulation in parental HeLa cells. The 
establishment of such a rescue assay has the advantage that it could also be used to 
perform “quasi-genetics” within cells by down-regulating the endogenous protein and 
studying the ability of different E6-AP mutants to rescue the phenotype. This approach 
would help to delineate the various biochemical properties of E6-AP required for its 
biological function. By identifying specific mutants of E6-AP which would specifically 
interact with only one or few of its substrates, this system would eventually help to 
study and characterize the individual E6-AP/substrate interactions within cells. 
One approach used for RNAi rescue is to overexpress the target gene in a form that is 
resistant to RNAi by introducing silent mismatches at the si/shRNA target site. Initial 
rescue experiments involving simultaneous knockdown of endogenous E6-AP 
expression and overexpression of E6-AP from a constitutive overexpression vector 
which is RNAi-resistant and monitoring of rescue by using colony formation assays 
revealed no rescue of the growth suppressive phenotype of E6-AP in HeLa cells (data 
not shown). This was not possible since constitutive overexpression of wild type E6-AP 
appears to be toxic to HeLa cells. In contrast, it was possible to stably overexpress E6-
AP in HPV-negative cell lines (namely H1299, RKO, and MCF-7) (Figure 27 and data 
not shown). 
While the reason for the inability to stably overexpress E6-AP in HPV-positive cells is 
unclear at the moment, it is interesting to note that it was possible to stably overexpress 
a construct of E6-AP lacking the E6 binding site (E6-AP-∆E6). One possible reason for 
this could be that since E6-AP-∆E6 is not targeted by E6 for degradation it can be 
overexpressed to high levels whereas overexpressed wild type E6-AP maybe expressed 
at undetectable levels due to the accelerated degradation by E6 under the experimental 
conditions used (Kao et al., 2000). However, even if this is the case, it does not answer 
the question why does the overexpressed wild type E6-AP construct have a negative 
effect on growth but not the E6-AP-∆E6 construct. A plausible reason could be that the 
18 amino acid E6 binding region on E6-AP is also important for other functions/ 
interactions of E6-AP. In this regard, it is interesting to note that the E6 binding region 
encompasses a short sequence motif LXXLL (where L is Leucine and X is any amino 
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acid) which has been shown to be sufficient for binding to liganded nuclear receptors. 
Furthermore, mutation of any of the leucines within this motif results in complete loss 
in ligand binding (Heery et al., 1997). E6-AP is known to act as a coactivator for 
nuclear hormone receptor independent of E6 (Nawaz et al., 1999). Thus, it can be 
speculated that overexpressed E6-AP leads to enhanced coactivator function within 
cells that would lead to its toxicity. Future work to determine which of the known E6-
AP activities (i.e E6 binding or receptor coactivation) is involved in this phenotype 
would require stable overexpression of mutants within this region which can 
differentiate between the two functions. Mutational analysis of the E6 binding region 
has indicated that mutation of the LXXLL motif to LXXLS does not have any effect on 
its ability to mediate p53 degradation (Cooper et al., 2003). Whether this mutant would 
abrogate the coactivator function of E6-AP is not yet known, but if so, overexpression 
of such a mutant could lead to insights into the toxicity effects of E6-AP in HeLa cells.  
The above arguments could account for the stable overexpression toxicity of E6-AP 
and require investigation. However, a simpler reason could also be that stable 
overexpression of E6-AP results in titrating out E6 within cells (as a result of binding to 
E6) and thus reducing the available free E6 protein required to perform the E6-AP-
independent functions of E6 within HPV-positive cells. If this is correct, both the E6-
AP-dependent and E6-AP-independent functions of E6 would be required for the 
viability of HPV-positive cancer cells. 
Since a stable phenotypic rescue of the growth suppressive phenotype using colony 
formation assays as a read out was not possible due to apparent toxicity of E6-AP 
overexpression, as an alternative strategy, transient rescue assay was tested using p53 
accumulation as a read out in HeLa cell line. As shown in Figure 28, while ectopically 
expressed E6-AP from an RNAi-resistant vector could rescue p53 accumulation 
brought about by down-regulation of endogenous E6-AP, an E6-AP construct lacking 
the E6 binding site did not rescue p53 accumulation. These data correlate with the 
biochemical evidence that E6 binding is required for E6-AP mediated ubiquitination of 
p53 (∆E6-E6-AP) (Huibregtse et al., 1993). By using different mutants of E6-AP, 
future work can employ such rescue experiments to perform “quasi genetics” within 
cells and study the various E6-AP/substrates interactions. In addition, it may be 
possible to design “quasi genetic” experiments to bring about a phenotypic rescue if 
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inducible expression vector systems are employed to regulate ectopically expressed E6-
AP expression to overcome the overexpression toxicity. 
5.6 E6-AP: A potential target for cervical cancer therapy? 
Comparison of HPV-positive and HPV-negative cell lines has indicated that, in case of 
HPV-positive cell lines, p53 is predominantly targeted for degradation by the E6/E6-
AP complex and that the Mdm2 pathway of p53 regulation is not, or only poorly active 
(Hengstermann et al., 2001). Indeed, studies using peptide aptamers or RNAi 
technology to target E6 expression have shown to result in the activation of p53-
dependent apoptotic pathways in HPV-positive cancer cells lines (Butz et al., 2000; 
Butz et al., 2003). In the present study, E6-AP was found to contribute to the anti-
apoptotic activities of E6 in HPV-positive cancer cells lines. The ability to activate p53-
dependent apoptotic pathways by interfering with either E6 or E6-AP expression 
suggests that these could be attractive targets for cervical cancer therapy.  
The ability to knockdown cancer or disease related genes using RNAi has led to the 
evaluation of the RNAi technology as a therapeutic agent in general. Although a 
number of obstacles (e.g. mode of delivery, stability) still need to be overcome before it 
becomes reality, proof of principle experiments in cell culture and animal model 
systems do show encouraging results that indicate it may prove to be helpful in cancer 
therapy (reviewed in Milner, 2003; Dorsett and Tuschl, 2004; Dillon et al., 2005; 
Dykxhoorn and Lieberman, 2005). With respect to using RNAi for cervical cancer 
therapy targeting of either the E6 or E7 proteins by RNAi has been suggested to be 
useful targets for therapy of cervical cancer (Jiang and Milner, 2002; Butz et al., 2003). 
While elimination of the viral oncoproteins would be an ideal target for therapy, the 
present study suggests that targeting of E6-AP in combination could have a cumulative 
effect in preferentially eliminating cancerous cells. However, since E6-AP is a cellular 
protein and, as suggested by the present study, complete elimination could have a 
negative effect on normal cells, further research would be necessary to determine a 
threshold level of E6-AP elimination at which minimal toxicity would occur to normal 
cells. Specific targeting of the RNAi molecules to tumor cells or selecting a suitable 
RNAi targeting sequence that would reduce E6-AP expression to a level wherein it 
would be toxic to HPV-positive cervical cancer cells and not normal cells could also 
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alleviate this problem. As an alternative approach, short term targeting of E6-AP 
expression could also lead to a preferential elimination of cervical cancer cells. 
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5.7 BiFC analysis 
The BiFC assay was developed to visualize protein-protein interactions in living cells 
by reconstitution of the yellow fluorescent protein from two fragments attached to two 
interacting proteins (Hu et al., 2002). In order to determine the subcellular localization 
of the interaction of E6-AP with its potential binding partners in living cells, an attempt 
was made to establish the BiFC assay.  
To initially test the reproducibility of this technique, experiments were performed using 
the positive controls of the bZIP domains of Fos and Jun fused to YFP fragments 
(bFosYC and bJunYN) (Hu et al., 2002). As reported by Hu et al, in my hands too, 
fluorescence complementation was only visualized when both constructs were 
expressed. To establish this technique for E6-AP, proof of principle experiments were 
performed using E6-AP and the RCC1b domain of HERC2. The logic behind choosing 
specifically HERC2 was due to the fact that interaction of HERC2 with E6-AP is well 
characterized in our lab (unpublished data). However, although interaction of the 
respective YFP fusions proteins of HERC2 with E6-AP could be detected in-vitro by 
GST-pull down assays (data not shown) and in-vivo by co-immunoprecipitation assays, 
this interaction could not be visualized by BiFC. Furthermore, subsequent experiments 
in our lab to study the binding of E6-AP with E6 by BiFC were also unsuccessful 
(Kostantin Matentzoglu, personal communication).  
The reason for the failure to visualize the interaction of E6-AP with HERC2 could be 
manyfold. Of these, the following were tested for and did not yield any positive result. 
To ensure that the two constructs were expressed in sufficient amounts, titration 
experiments were performed. However, no fluorescence complementation was 
observed even at rather high expression levels (data not shown). To rule out the 
possibility that the YFP fragments in the context of the fusion proteins could be 
spatially too far apart to reconstitute the fluorophore, the YFP fragments were cloned 
either at the N-terminus or at the C-terminus of E6-AP/RCC1b domain of HERC2. 
Furthermore, whereas the C-terminal fusion construct of E6-AP is defective for 
substrate ubiquitination (Salvat et al., 2004), to rule out that the activity of E6-AP per 
se (i.e ubiquitination) could interfere with complementation by targeting the interacting 
partner for degradation, N-terminal fusion constructs of E6-AP were also generated 
with a catalytically inactive mutant of E6-AP (C820A). These constructs were 
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transfected in different combinations (e.g. N-terminal YFP fusion of E6-AP with C-
terminal YFP fusion of RCC1b or vice versa) into various cell lines and monitored for 
interaction. However, no fluorescence complementation was observed. 
Further to this, it could be possible that proper folding of the YFP fragment as a fusion 
with E6-AP/RCC1b domain results in steric hindrance and thus prevents 
complementation. Since the constructs used possess a linker sequence between the YFP 
fragment and E6-AP/RCC1b, in order to rule out that this linker sequence is 
insufficient, in future experiments, one should generate constructs with other linker 
sequences and check for complementation. Furthermore, additional interacting partners 
should be tested to determine whether the lack of fluorescence complementation is 
dependent on the interacting protein.  
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7. Zusammenfasung 
Die Ubiquitin-Proteinligase E6-AP wurde ursprünglich als ein Protein identifiziert, das 
mit dem E6-Onkoprotein humaner Papillomaviren (HPVs) interagieren kann. 
Bestimmte HPVs spielen bei der Entstehung des Cervixcarcinoms eine kausale Rolle. 
Dabei bindet der E6/E6-AP Komplex an das Tumorsuppressorprotein p53 und führt so 
zu dessen Ubiquitinierung und anschließendem proteasomalen Abbau. Außer p53 
werden weitere zelluläre Proteine E6/E6-AP-abhängig ubiquitiniert und abgebaut. Die 
Rolle dieser Interaktionen für die Cervixcarcinogenese ist aber noch unklar. 
Im Gegensatz zu den meisten Krebsarten, bei denen p53 entweder mutiert vorliegt oder 
überhaupt nicht exprimiert wird, wird in HPV-positiven Cervixcarcinomen Wildtyp-
p53 exprimiert. Dies lässt die Annahme zu, dass eine funktionelle Inaktivierung von 
p53 durch E6/E6-AP mit einer Inaktivierung durch Mutation gleichgesetzt werden 
kann. Um die Bedeutung von E6-AP für die Lebensfähigkeit HPV-positiver 
Krebszellen zu untersuchen, wurde in dieser Arbeit die Methode der RNA-Interferenz 
angewandt, um die Expression von E6-AP spezifisch abzuschalten. Suppression der 
E6-AP-Expression resultierte in der Akkumulation von p53 und einer 
Wachstumsinhibition der behandelten Zellen. Des Weiteren reagierten HeLa-Zellen, in 
denen die Expression von p53 durch RNA-Interferenz stabil reprimiert ist, signifikant 
weniger sensitiv auf eine Inhibition der E6-AP-Expression als parentale HeLa Zellen. 
Diese Daten deuten darauf hin, dass die für das Wachstum HPV-positiver Zellen 
notwendige Aktivität von E6-AP auf seiner Eigenschaft basiert, im Komplex mit E6 
p53 zu ubiquitinieren und somit zu dessen Abbau zu führen. 
Mutationen im E6-AP Locus (UBE3A), die in einer funktionellen Inaktivierung von 
E6-AP resultieren, sind für eine erbliche neurologische Erkrankung, dem Angelman-
Syndrom, verantwortlich. Um die Bedeutung von E6-AP für die Lebensfähigkeit von 
HPV-negativen Zellen zu untersuchen, wurde die E6-AP-Expression durch RNA-
Interferenz entweder transient oder stabil reprimiert. Die Tatsache, dass es im 
Gegensatz zu HPV-positiven Zellen möglich war, die E6-AP-Expression stabil zu 
reprimieren, lässt den Schluss zu, dass unter den gegebenen Bedingungen HPV-
negative Zellen weniger sensitiv auf eine Unterdrückung der E6-AP-Expression 
reagieren als HPV-positive Zellen. Allerdings war es nicht möglich, klonale Zelllinien 
zu erhalten, in denen die E6-AP-Expression vollständig abgeschaltet war. Dies 
unterstützt die Hypothese, dass auch für die Lebensfähigkeit HPV-negativer Zellen eine 
bestimmte Menge an E6-AP essenziell ist. Nichtsdestotrotz scheint für die 
Lebensfähigkeit HPV-negativer Zellen ein deutlich niedrigerer Level an E6-AP 
ausreichend zu sein als für HPV-positive Zellen. Daher mag E6-AP ein potenzielles 
Zielprotein für die Therapie von HPV-positiven Cervixcarcinomen sein. 
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8. Abstract 
The cellular ubiquitin-protein ligase E6-AP was initially identified as a protein that 
interacts with the E6 oncoprotein of Human papillomaviruses (HPVs) associated with 
cervical carcinomas. Subsequently, this E6/E6-AP complex has been shown to bind and 
target the tumour suppressor protein p53 for ubiquitin-mediated proteasomal 
degradation. In addition to p53, the E6/E6-AP complex also targets other cellular 
proteins for ubiquitin-mediated proteasomal degradation. However, the significance of 
these interactions in cervical carcinogenesis remains unclear. 
In contrast to most cancers wherein the p53 gene is mutated or not expressed, it is 
rarely mutated in HPV-positive cervical carcinomas. This has led to the assumption that 
functional inactivation of p53 by the E6/E6-AP complex is equivalent to its inactivation 
by mutation. To understand the significance of E6-AP for the viability of HPV-positive 
cells, in this study, E6-AP expression was down-regulated by RNA interference 
(RNAi) in HPV-positive cervical cancer cell lines. This resulted in p53 accumulation 
and growth suppression. Furthermore, HeLa cells, in which p53 expression was stably 
suppressed by RNAi, were found to be significantly less sensitive to the down 
regulation of E6-AP expression with respect to growth suppression than parental HeLa 
cells. These data indicate that E6-AP has anti-growth-suppressive properties in HPV-
positive cells and that these depend on its ability to induce p53 degradation. 
Mutations within the E6-AP locus (UBE3A) resulting in functional inactivation of E6-
AP have been associated with Angelman syndrome, an inherited human neurological 
disorder. To further elucidate the importance of E6-AP for the viability of HPV-
negative cells, E6-AP was down-regulated by RNAi either transiently or stably in 
HPV-negative tumour cell lines. In contrast to HPV-positive cell lines, it was possible 
to obtain clonal HPV-negative cell lines in which E6-AP was stably down-regulated by 
RNAi. This would indicate that under the given conditions, HPV-negative cells are less 
sensitive to E6-AP down-regulation than HPV-positive cells. However, the inability to 
obtain clonal cell lines in which E6-AP expression is completely abrogated supports the 
hypothesis that certain threshold levels of E6-AP expression is essential for normal cell 
viability. Taken together, these results suggest that in comparison to HPV-positive 
cells, HPV-negative cells require lower threshold levels of E6-AP expression for 
viability and thus selective targeting of E6-AP function may have therapeutic potential 
against HPV-induced cervical carcinogenesis. 
 
Erklärung 
 102
9. Erklärung 
Ich versichere, daß ich die von mir vorgelegte Dissertation selbständig angefertigt, die 
benutzten Quellen und Hilfsmittel vollständig angegeben und die Stellen der Arbeit -
einschließlich Tabellen, Karten und Abbildungen -, die anderen Werken im Wortlaut 
oder dem Sinn nach entnommen sind, in jedem Einzelfall als Entlehnung kenntlich 
gemacht habe; daß diese Dissertation noch keiner anderen Fakultät oder Universität zur 
Prüfung vorgelegen hat; daß sie-abgesehen von unten angegebenen Teilpublikationen -
noch nicht veröffentlicht worden ist sowie, daß ich eine solche Veröffentlichung vor 
Abschluß des Promotionsverfahrens nicht vornehmen werde. Die Bestimmungen dieser 
Promotionsordnung sind mir bekannt. Die von mir vorgelegte Dissertation ist von Prof. 
Dr. Mats Paulsson betreut worden. 
 
 
Köln, Nov 2005                ------------------------- 
        (Michael D’silva) 
 
 
Teilpublikationen im Rahmen dieser Arbeit: 
 
Arnd Hengstermann*, Michael A. D'Silva*, Petric Kuballa, Karin Butz, Felix Hoppe-
Seyler and Martin Scheffner (2005). "Growth suppression induced by downregulation 
of E6-AP expression in human papillomavirus-positive cancer cell lines depends on 
p53." J Virol 79(14): 9296-300. 
 
Lebenslauf 
 103
10. Lebenslauf 
Name und Anschrift Michael Aloysius D’silva 
Appt Nr. 529, West I,  
Werner-Sombart Str.37 
78464, Konstanz 
Telefon: 0179-6837323 
Geboren am 09 Juli, 1976 
Geburtsort Mysore, Indien 
Staatsangehörigkeit Indisch 
 
Schulausbildung  
1989-1992 S.S.L.C (Secondary School Leaving Certificate), 
Mysore, Indien  
1992-1994 P.U.C (Pre-University Certificate), Mysore, Indien 
 
Hochschule  
1994-1997  B.Sc (Bachelor of Science), Universität zu Mysore, 
 Mysore, Indien 
1997-1999 
 
M.Sc (Master of Science), Universität zu Mysore, 
Mysore, Indien 
1999-2001 Project Assistant  
in der Arbeitsgruppe von Prof. Dr. H.S Savithri 
Indian Institute of Science, Bangalore 
Indien 
2001-2005 Promotion, Universität zu Köln  
Thema: “Characterization of the Ubiquitin-Protein 
Ligase E6-AP by RNA interference” 
Durchführung der Promotion in der Arbeitsgruppe von 
Prof. Dr. Martin Scheffner am Institut für Biochemie I, 
Medizinische Fakultät, Universität zu Köln, Köln und 
am Fachbereich Biologie, Universität zu Konstanz, 
Konstanz. 
Betreuung der Promotion durch Prof. Dr. Mats 
Paulsson, Institut für Biochemie II, Universität zu 
Köln, Köln 
 
  
 
 104
  
 0
